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The prevalence of food allergies is higher in children compared to adults and it is increasing. 
The factors that influence food allergies in children are not clear. In light of the hygiene 
hypothesis, vaccinations may contribute towards to a predominant allergen specific response 
or exposure to the virus or microbe in the vaccine may decrease the risk for allergy. Previous 
studies have shown that the effect of vaccinations on food allergy and food sensitisation 
varies. Therefore, the aim of this study is to determine if a relationship exists between 
vaccinations and food allergies and food sensitisation in children in the first 18 months of life 
who live in urban Cape Town and in rural Mqanduli in the Eastern Cape. Secondary data 
analysis of an observational cross sectional study was carried out which involved univariate 
logistic regression to calculate odds ratios between self-reported immunisation status and 
food sensitisation and food allergy at a 95% confidence interval in children between 12 and 
36 months of age. The same method was employed to investigate the relationship between 
immunisation and atopy. Multivariate analysis was utilised to adjust for potential 
confounders. Food sensitisation and food allergy were determined through skin prick tests 
(SPT) and oral food challenges respectively. The results indicate that, the number of 
participants positive for food sensitisation and allergy, eczema, hay fever and asthma were 
significantly greater in the urban sample (n= 708)  compared to the rural sample (n= 400) 
(P<0.05). Further, in 708 urban children, those who had a BCG vaccine at birth were 0.05 (OR 
0.05; 95% CI: 0.004 - 0.6) times less likely to have an SPT  7mm. The BCG unvaccinated cohort 
consisted of three individuals. There were no other significant associations between 
childhood vaccinations and food sensitization at SPT 1mm, 3mm and 7mm. There was no 
significant association between vaccinations and food allergy or other forms of atopy. In 
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conclusion, there was very little evidence of an association between BCG vaccination in 
children and food allergic sensitisation or food allergy. However, in a small subgroup, there 
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Part A Protocol 
The relationship between immunisation and food allergy and sensitisation in 
South African children 
Purpose of the study 
 
The aim of this research is to determine if an association exists between vaccinations and 
food sensitisation and food allergy in children in the first 18 months of life who live in urban 
Cape Town and rural Mqanduli in the Eastern Cape. The hypothesis is that immunisation is 
correlated with food sensitisation and food allergy in children from South Africa. 
Rationale & background information 
 
Immediate type food allergy is defined by the World Health Organisation (WHO) as the 
development of an immune reaction within an hour to a specific food consumed (WHO and 
INFOSAN, 2006). A food allergy is either Immunoglobulin E (IgE) mediated or non IgE mediated 
(WHO and INFOSAN, 2006). IgE mediated food sensitization can be determined through a skin 
prick test (SPT) or through the identification of allergen specific IgE antibody in an individual’s 
blood (Gray et al., 2014).  While the presence of food sensitisation is a pre-requisite for a 
diagnosis of food allergy, only some people with food sensitisation will go on to develop food 
allergy (WHO and INFOSAN, 2006). IgE mediated food allergies are confirmed through food 
challenge testing (Gray et al., 2014). 
It is estimated that 1-10% of people suffer from a food allergy worldwide (Rona et al., 2007). 
When the prevalence of common food allergies was investigated in Europe, lifetime 
prevalence was found to be; 0.33-6% for cow’s milk, 0.23- 3.61% for egg allergy, 0.30- 3.61% 
wheat allergy, 0.26-3.16% soy allergy, 0.22- 8.58% for peanut allergy, 0.45-1.32% for tree nut 
allergy, 0.62- 2.17% for fish allergy and 0.70-1.31% for shellfish allergies (Nwaru et al., 2014). 
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Food allergy prevalence was determined through self-reporting, open food challenge (OFC), 
skin prick testing (SPT) or specific immunoglobulin E (IgE) testing (Nwaru et al., 2014). 
The prevalence of some food allergies is higher in children compared to adults. A meta-
analysis found that children less than one year old had cow’s milk and egg allergy prevalence 
of 2% and 0.71% respectively compared to 0.61% and 0.23% in adults (Nwaru et al., 2014). 
Many children outgrow food allergies (Kattan, 2016), over ten years the cumulative incidence 
of food hypersensitivity decreased by 3.2% in a prospective study (Venter et al., 2016). 
Therefore, the prevalence of food allergy is higher in children. 
The prevalence of food allergies amongst children in South Africa is not well described. One 
study reported food allergy prevalence amongst children between 6 months and 10 years 
with severe atopic dermatitis to be 40% (Gray et al., 2014). Food allergy was confirmed using 
OFC once sensitisation had been established using SPT, IgE blood testing and clinical history 
(Gray et al., 2014). Atopic dermatitis is a type of eczema which is an acknowledged risk factor 
for food allergies (Gray et al., 2014). Recently, results were published indicating a prevalence 
of food sensitization (SPT1mm) to be 12.3% and food allergy to be 2.5% amongst 512 urban 
Cape Town children between 12 and 36 months of age (Basera et al., 2015). With regards to 
food allergies, the study reported a prevalence of food allergies confirmed through an oral 
food allergy test to be 1.8%, 0.2%, 1.2% and 0.2% for egg, cow’s milk, peanut, and fish 
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Table A1: South Africa vaccine schedule 
Time Vaccination Time Vaccination 
Birth BCG 14 weeks RV(2)  
 OPV (0) DTaPIPV/HiB(3)  
6 weeks OPV (1)  HBV(3)  
RV (1)  PCV7 or 13 (2)  
DTaPIPV/HiB (1)  9 months Measles vaccine  
HBV (1)  PCV 7 or 13 (3)  
PCV7 or 13(1)  18 months DTaPIPV/HiB (4) 
10 weeks DTaPIPV/HiB (2)  Measles Vaccine 
HBV (2)    
 
Vaccines are offered routinely to children in South Africa (Table A1). Vaccines may act as 
modifiable protective factors or risk factors for food sensitisation and food allergies in South 
African children. It has previously been hypothesised that a lack of early childhood exposure 
to microbes and infections in the modern era has led to an increase in atopic disorders 
(Obihara and Bardin, 2008). This phenomenon is coined as the “hygiene hypothesis” 
(Strachan, 1989). Following from this theory, research has been carried out to determine 
whether attenuated infectious agents in vaccinations may reduce or increase the incidence 
of atopic disorders (Obihara and Bardin, 2008).  
BCG vaccine 
An inverse relationship between the Mycobacterium Tuberculosis Bacillus Calmette–Guerin 
(BCG) vaccine and atopic diseases has been identified in studies carried out in different parts 
of the world (Obihara and Bardin, 2008). In Guinea Bissau, children who had a BCG vaccination 
scar and documentation confirming BCG vaccination had a 59% (OR 0.41; 95% CI: 0.22- 0.76) 
decreased odds for atopy (any SPT wheel 2) (Aaby et al., 2000). Similarly, a study showed 
that children who had a BCG vaccination scar had a 58% (OR 0.42; 95% CI: 0.19–0.94) reduced 
odds of atopy (any SPT wheel 3mm to egg white, peanuts, cow’s milk, house dust mites or 
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cockroach) compared to those without a scar (Kiraly et al., 2013). The same study found that 
the time of BCG vaccination, early or delayed, was not significantly associated with atopy 
(Kiraly et al., 2013). These studies point to the possibility of childhood vaccines being 
protective for atopy, food sensitisation and allergies in other populations in Africa. 
Contrastingly, in 2014, a systematic review and meta-analysis reported no significant 
association between BCG and self-reported asthma, eczema, rhinoconjunctivitis and other 
common allergies in children between 13 to 17 years of age (Linehan et al., 2014). Different 
results from previous studies looking at similar associations between vaccines and allergy-
related outcomes indicate the importance of carrying out further research that will add 
towards reaching definitive conclusions on allergies. 
DTP vaccine 
The Diphtheria, Tetanus and Pertussis (DTP) vaccine which is administered to infants in South 
Africa at 6, 10, 14 and 72 weeks (Amayeza-Information-Services, 2015) may be a risk factor 
for atopy, protective against atopy or not associated with atopy disorders. A British study 
found an association between diphtheria, polio, pertussis, and tetanus (DPPT) vaccination and 
incident diagnosed asthma (OR 10.33; 5.36- 19.91) and incident diagnosed eczema (OR 7.51; 
5.27- 10.70) in infants in the first 6 months of life, when controlling for GP visits (McKeever et 
al., 2004). Atopic dermatitis (eczema) is a risk factor for food allergies (Heratizadeh et al., 
2011) and this may point to DTP as a possible risk factor for food sensitisation and allergies in 
children. Contrastingly, in a Swedish study, no significant association was identified between 
asthma medication use and DTP (Vogt et al., 2014). This study investigated asthma in 
adolescent participants who were exposed to DTP as children (Vogt et al., 2014). Delaying a 
vaccination may be protective for atopy. This is demonstrated by a cross sectional study 
carried out in Melbourne, Australia, that reported DTaP administered with a month delay was 
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associated with a reduced risk of doctor diagnosed eczema (OR 0.57; 0.34- 0.97, p=0.04) 
compared to when the vaccine was administered at the standard time in one year old infants 
(Kiraly et al., 2016). These studies indicate that DTaP and DPPT have the possibility to be a risk 
factor for atopy, protective against atopy or not associated with atopy disorders. Inconclusive 
results on the association and type of association warrants further research to determine the 
relationship between DTP and atopy including food allergies and sensitisation. 
MMR vaccine 
A measles vaccine at the time of the study was administered at 9 months and 18 months to 
children through the public health sector in South Africa (Amayeza-Information-Services, 
2015),   changed in 2016 to 6 and 12 months (NICD, 2016). In the Faroe Islands, the measles 
mumps and rubella (MMR) vaccine was found to be significantly associated with a reduced 
odds of 0.16 (0.05 - 0.53) of getting clinically examined asthma in 13 year old children 
(Timmermann et al., 2015). An additional study found the opposite association where MMR 
significantly increased the risk of incident diagnosed eczema (hazard ratio 4.61; 3.15- 6.74) 
and asthma (hazard ratio 3.51; 2.42- 5.11) (McKeever et al., 2004) in infants in the first 6 
months of life. It is not known which component of MMR may be responsible for reducing or 
increasing the risk of asthma and eczema. 
The studies described above indicate associations between vaccinations and atopy in first 
world countries and one indicating an association in a West African country (McKeever et al., 
2004, Kiraly et al., 2013, Timmermann et al., 2015, Aaby et al., 2000). Determining if similar 
associations exist for a South African population will provide important insights into the 
factors associated with allergies in South Africa. Although the studies do not provide 
information on the association between food sensitisation or allergy and immunisation, the 
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association found between vaccines and atopy provide grounds for research into vaccines and 
food sensitisation and allergy. 
The South African Food sensitisation Food Allergy (SAFFA) study is being carried out to 
investigate the prevalence of IgE mediated food allergy in South African children (Levin et al., 
2013). Furthermore this study aims to investigate modifiable and non-modifiable risk factors 
and protective factors for food allergies and food sensitisation in children from South Africa 
(Levin et al., 2013). Thus, as a subpart of the SAFFA study, the aim of this study is to determine 
if a relationship exists between food allergies and vaccinations administered to children in the 
first 18 months of life who live in urban Cape Town and rural Mqanduli, in the Eastern Cape. 
Study goals and objectives 
The aim of the research is to determine if a relationship exists between vaccinations and food 
allergy and food sensitisation in children in the first 18 months of life who live in urban Cape 
Town and in rural Mqanduli in the Eastern Cape. 
Objectives 
1. To describe the pattern of immunisation coverage in South African children  
2. To compare the pattern of immunisation coverage in rural and urban South African 
children  
3. To investigate the relationship between immunisation (appendix 1) administered up 
until 18 months and food allergy and food sensitisation (egg, cow’s milk, soy, wheat, 
fish, peanut and hazel nut) in children between 12 and 18 months. 
4. To investigate the relationship between immunisation (appendix 1) administered up 
until 18 months and self-reported asthma, hay fever and eczema in children 
between 12 and 18 months. 
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Study Design  
The study design will be an observational cross sectional study carried out using secondary 
data analysis at the Red Cross War Memorial Hospital in Cape Town. All children tested for 
food sensitisation will be selected from the SAFFA database and vaccinations previously 
administered will be assessed.   
 
Power to carry out study 
In order to carry out this study, the probability that the tests carried out will result in a 
significant difference at a 95% significance level (= 0.05), the power of the test will be set at 
80% (1- ). To calculate the power to test whether immunisation is significantly associated 
with food sensitisation, the immunisation coverage in children with food sensitisation and 
allergy compared to those without in South Africa, will be required. South African 
immunisation coverage ranges from 55.2%-100% nationwide and coverage is 92.6% in urban 
Cape Town (Massyn et al., 2013).  There is no data indicating the coverage of vaccination 
amongst children who are sensitised or allergic to foods in South Africa. Therefore, an 
estimated figure for the exposure of vaccination will be used from the Abby et al., (2000) 
paper, which reports that immunisation coverage in children with atopy is 73% (Aaby et al., 
2000). Further, the Urban Cape Town cohort of the SAFFA study consists of a sample size of 
668 where 12.3% tested positive from a SPT with a reactive wheal 1mm, 9.6% tested positive 
from a SPT with a reactive wheal  3mm and 4.5% tested positive from a SPT with a reactive 
wheal  7mm (Basera et al., 2015) (Table A2). Power calculations indicate that there is enough 
power to perform tests looking at vaccine exposure in sensitised and non-sensitised for those 
found positive for a SPT greater than 1mm and 3 mm (Table A2). However, there isn’t enough 
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power (68.3%) to detect a significant association (= 0.05) for participants with a SPT reactive 
wheal greater than 7mm (Table A2). 
 
Table A2: Table showing variables for URBAN cohort utilised to calculate power to investigate 
association between immunisation and different levels of sensitisation 




 3mm  7mm 







(n total= 668) 




73% 90% 73% 90% 73% 90% 
Power to find a 
difference % 
95.9% 91.7% 68.3% 
Urban cohort 
 
The estimated immunisation coverage in the OR Tambo district where Mqanduli is located is 
approximately 75% in under 1 year olds (Massyn et al., 2013). The rural Eastern Cape cohort 
includes 400 participants and the number of participants who are positive for food 
sensitisation (reactive wheal  1mm) is 18 (4.5%). If an immunisation coverage of 73% (Aaby 
et al., 2000) is used as an estimate for those immunised in the food sensitised participants, 
the study is insufficiently powered (3.4%) for an investigation into the relationship between 
food sensitization and the exposure of immunisation in the rural cohort (Table A3). However, 
the prevalence of immunisation in food sensitised children from rural areas in South Africa is 
unknown. If it is found that immunisation coverage is 40% or less in the sensitised rural 
participants, then the investigation will be adequately powered (Table A3). Therefore this part 
of the study may nevertheless be carried out due to it being the first of its kind being 
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Table A3: Table showing variables for RURAL cohort utilised to calculate power to carry out 
analysis between sensitisation and immunisation for different levels of immunisation coverage in 
sensitised participants 
n total = 400 
Prevalence 
Sensitised  (SPT  1mm) 




Estimated immunisation coverage % 95 75 28.9 
Estimated immunisation coverage % 73 75 3.4 
Estimated immunisation coverage % 65 75 11.9 
Estimated immunisation coverage % 40 75 82.9 
Rural cohort 
 
Characteristics of the study population 
A group of 708 urban Cape Town participants and 400 rural Eastern Cape participants will be 
utilised for the study. Study participants will comprise of children between 12-36 months of 
age from registered crèches in metropolitan Cape Town and from communities surrounding 
health centres in Mqanduli in rural Eastern Cape.  
Inclusion criteria for participants 
 Participants who are between 12 and 36 months. Children who are less than 18 
months will not be assessed for vaccines at 18 months. 
 Tested for food sensitization by means of a skin prick (SPT 1mm, 3mm and 7mm) 
test to the following foods; egg, cow’s milk, soy, wheat, fish, peanut and hazel nut. 
 If sensitised tested for food allergy to at least one; egg, cow’s milk, soy, wheat, fish, 
peanut and hazel nut, through an oral food challenge. 
 Participants with self-reported information on asthma, hay fever and eczema 
 
Exclusion criteria  
 Participants with missing or unclear information for food allergy and food sensitisation 
tests. 
 Participants with missing or unclear information on vaccination status. 
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Recruitment and enrolment 
Secondary data analysis will be employed for this study. Thus, data for participants will be 
collected from the database of the SAFFA study. The SAFFA study acquired its data through 
administering a questionnaire to parents and guardians and performing skin prick tests and 
oral food challenge tests on participants. All children with data in the SAFFA database will be 
included unless they are deemed to be ineligible by the principal investigator and supervisor 
in terms of the inclusion and exclusion criteria outlined above. 
 
Research procedures data collection methods 
As mentioned previously, the SAFFA study collected data using questionnaires and confirmed 
food allergy and sensitization through clinical history and food allergy and sensitization tests. 
The current investigation will not collect data directly from participants because secondary 
data analysis will be carried out. 
 
Data safety and monitoring 
 
Data analysis 
Describe the pattern of immunisation coverage in South African children  
 Exploratory data analysis will be performed through the use of descriptive measures, 
frequency distributions and graphs such as bar graphs, pie charts and histograms for 
each vaccine. 
To compare the pattern of immunisation coverage in rural and urban South African children  
 Exploratory data analysis will be performed through the use of descriptive measures, 
frequency distributions and graphs such as bar graphs, pie charts and histograms for 
each vaccine for the rural and urban cohort separately. 
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To investigate the relationship between immunisation and food allergy and food 
sensitisation  
 Chi squared test between immunisation and food sensitisation will be carried out to 
investigate a possible association. 
 As this is a cross sectional study prevalence ratios will be calculated to investigate 
the relationship between immunisation and food allergy and food sensitisation. 
 Multivariate logistic regression analysis will be utilised to investigate the risk or 
protection of food sensitisation when exposed to various vaccinations while 
accounting for potential confounders. 
To investigate the relationship between immunisation and self-reported asthma, hay fever 
and Eczema. 
 Chi squared test between immunisation and self-reported asthma, hay fever and 
eczema will be carried out to investigate a possible association. 
 Prevalence ratios will be calculated to investigate the relationship between 
immunisation and self-reported asthma, hay fever and eczema. 
 Multivariate regression analysis will be utilised to investigate the risk of asthma, hay 
fever and eczema when exposed to various vaccinations while being conscious that 
asthma, hay fever and eczema were self-reported measures. 
 
Ethical considerations 
The study seeks to investigate a phenomenon in a vulnerable population group, which are 
children between 12 and 36 months of age. Therefore risks, benefits and confidentiality are 
important factors to consider in this research. The SAFFA study on children between 12- 36 
13 
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months was approved by the human ethics committee at the University of Cape Town. Ethics 
approval was received on January 2013. For the current study “The relationship between 
immunisation and food allergy and sensitisation in South African children”, ethics approval to 
perform secondary data analysis will be required. 
Risks  
The study involves secondary data analysis and the risks for participants will be low. The 
SAFFA database does not contain names and recognisable personal patient information. 
Unique numerical identifiers are used to differentiate participants on the database. The 
names of the participants and any other direct personal information can only be accessed by 
the principal investigator of the SAFFA study. However, it is possible that while the study is 
being carried out, one might need to refer to a participant questionnaire for clarification of a 
certain variable and in the process, come across personal information. If this happens, 
personal identifying information will not be included and the risk in breaching confidentiality 
will be kept at a minimum.  
 
Benefits 
The participants of this study will not directly benefit from this study, however the knowledge 
gained form the study has positive implications for children. At a societal level, the study will 
contribute to the knowledge and understanding of risk factors or protective factors associated 
with food allergy and sensitisation among South African children. This will assist health 
workers to predict risks or protective elements and assist with preventing food allergies and 
sensitisation associated with vaccinations. Further, this research will allow for patients to be 
advised on whether vaccines have an association with food sensitisation and allergy. 
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Informed consent process 
Informed consent was obtained from guardians and parents for all participants in the SAFFA 
study. Therefore all study participants loaded on the SAFFA study database have provided 
informed consent for the relationship between vaccines and food sensitisation and allergy to 
be carried out. In the current study, information from the database will be used and there will 
be no patient contact between the researcher and the participants.  
 
Privacy and confidentiality 
To ensure respect for participants in this study, confidentiality of participation in research will 
be maintained throughout the entire study and thereafter. Names and personal information 
of participants can only be accessed by the principal investigators of the SAFFA study. This 
information will not be available on the database, rather anonymous numerical identifiers 
will be used to identify participants. In this way the confidentiality of participants will be 
protected. Further, all electronic files used in the current study will be password protected. 
 
Dissemination 
The results of this research will be published as a journal article to share the information 
obtained with the larger allergy clinical and scientific research body. Further, the findings of 
this research will be made available to those in the department of paediatrics and child health, 
to contribute towards better knowledge on modifiable factors for paediatric food allergies 





Part A Protocol 
References 
 
AABY, P., SHAHEEN, S. O., HEYES, C. B., GOUDIABY, A., HALL, A. J., SHIELL, A. W., JENSEN, H. 
& MARCHANT, A. 2000. Early BCG vaccination and reduction in atopy in Guinea-Bissau. Clin 
Exp Allergy, 30, 644-50. 
AMAYEZA-INFORMATION-SERVICES. 2015. Vaccine Schedules for South Africa for 2015 
[Online]. Amayeza Information Services Available: http://www.amayeza-info.co.za/ 
[Accessed 15/10/2015 2015]. 
BASERA, W., BOTHA, M., GRAY, C. L., LUNJANI, N., WATKINS, A. S., VENTER, C., ALLEN, K. J., 
HLELA, C., ZAR, H. J. & LEVIN, M. E. 2015. The South African Food Sensitisation and Food 
Allergy population-based study of IgE-mediated food allergy: validity, safety, and 
acceptability. Ann Allergy Asthma Immunol, 115, 113-9. 
GRAY, C. L., LEVIN, M. E., ZAR, H. J., POTTER, P. C., KHUMALO, N. P., VOLKWYN, L., 
FENEMORE, B. & DU TOIT, G. 2014. Food allergy in South African children with atopic 
dermatitis. Pediatr Allergy Immunol, 25, 572-9. 
HERATIZADEH, A., WICHMANN, K. & WERFEL, T. 2011. Food allergy and atopic dermatitis: 
how are they connected? Curr Allergy Asthma Rep, 11, 284-91. 
KATTAN, J. 2016. The Prevalence and Natural History of Food Allergy. Curr Allergy Asthma 
Rep, 16, 47. 
KIRALY, N., BENN, C. S., BIERING-SORENSEN, S., RODRIGUES, A., JENSEN, K. J., RAVN, H., 
ALLEN, K. J. & AABY, P. 2013. Vitamin A supplementation and BCG vaccination at birth may 




Part A Protocol 
KIRALY, N., KOPLIN, J. J., CRAWFORD, N. W., BANNISTER, S., FLANAGAN, K. L., HOLT, P. G., 
GURRIN, L. C., LOWE, A. J., TANG, M. L., WAKE, M., PONSONBY, A. L., DHARMAGE, S. C. & 
ALLEN, K. J. 2016. Timing of routine infant vaccinations and risk of food allergy and eczema 
at one year of age. Allergy, 71, 541-9. 
LEVIN, M., GREY, C. & HLELA, C. 2013. The South African Food sensitisation and Food Allergy 
study: A cross-sectional, observational study of IgE-mediated food allergy in an unselected 
population of South African children aged 12-36 months. Protocol V10.7. South Africa: 
University of Cape Town . Red Cross War Memorial Children’s Hospital. 
LINEHAN, M. F., NURMATOV, U., FRANK, T. L., NIVEN, R. M., BAXTER, D. N. & SHEIKH, A. 
2014. Does BCG vaccination protect against childhood asthma? Final results from the 
Manchester Community Asthma Study retrospective cohort study and updated systematic 
review and meta-analysis. J Allergy Clin Immunol, 133, 688-95 e14. 
MASSYN, N., DAY, C., BARRON, P., HAYNES, R., ENGLISH, R. & PADARATH, A. 2013. District 
Health Barometer 2011/2012. In: TRUST, H. S. (ed.) The District Health Barometer. Durban: 
Health Systems Trust. 
MCKEEVER, T. M., LEWIS, S. A., SMITH, C. & HUBBARD, R. 2004. Vaccination and allergic 
disease: a birth cohort study. Am J Public Health, 94, 985-9. 
NICD 2016. Communicable Diseases Communiqué. In: DEPTOFHEALTH (ed.). Johannesburg: 
National Institute for Communicable Diseases 
NWARU, B. I., HICKSTEIN, L., PANESAR, S. S., ROBERTS, G., MURARO, A., SHEIKH, A., 
ALLERGY, E. F. & ANAPHYLAXIS GUIDELINES, G. 2014. Prevalence of common food allergies 
in Europe: a systematic review and meta-analysis. Allergy, 69, 992-1007. 
17 
 
Part A Protocol 
OBIHARA, C. C. & BARDIN, P. G. 2008. Hygiene hypothesis, allergy and BCG: a dirty mix? Clin 
Exp Allergy, 38, 388-92. 
RONA, R. J., KEIL, T., SUMMERS, C., GISLASON, D., ZUIDMEER, L., SODERGREN, E., 
SIGURDARDOTTIR, S. T., LINDNER, T., GOLDHAHN, K., DAHLSTROM, J., MCBRIDE, D. & 
MADSEN, C. 2007. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol, 
120, 638-46. 
STRACHAN, D. P. 1989. Hay fever, hygiene, and household size. BMJ : British Medical 
Journal, 299, 1259-1260. 
TIMMERMANN, C. A., OSUNA, C. E., STEUERWALD, U., WEIHE, P., POULSEN, L. K. & 
GRANDJEAN, P. 2015. Asthma and allergy in children with and without prior measles, 
mumps, and rubella vaccination. Pediatr Allergy Immunol, 26, 742-9. 
VENTER, C., PATIL, V., GRUNDY, J., GLASBEY, G., TWISELTON, R., ARSHAD, S. H. & DEAN, T. 
2016. Prevalence and cumulative incidence of food hyper-sensitivity in the first 10 years of 
life. Pediatric Allergy and Immunology, 27, 452-458. 
VOGT, H., BRABACK, L., KLING, A. M., GRUNEWALD, M. & NILSSON, L. 2014. Pertussis 
immunization in infancy and adolescent asthma medication. Pediatrics, 134, 721-8. 
























Part B Literature Review 
Part B: Literature Review 
 
Contents Literature Review 
 
 
Part B: Literature Review ........................................................................................................... 1 
Contents Literature Review ....................................................................................................... 1 
Introduction ........................................................................................................................... 2 
Food allergy ........................................................................................................................ 2 
Atopy .................................................................................................................................. 3 
Hygiene hypothesis ............................................................................................................ 4 
Objectives............................................................................................................................... 6 
Literature Search strategy ..................................................................................................... 6 
Summary and interpretation of literature ........................................................................... 14 











Food allergy is defined as an immune mediated individual hypersensitivity reaction to food 
(WHO and INFOSAN, 2006).  Subtypes of food allergy include IgE mediated food allergy which 
occurs within two hours of a specific food consumed and non-IgE mediated or “delayed type” 
food allergy (ASCIA, 2016, WHO and INFOSAN, 2006). While the presence of food sensitisation 
is a pre-requisite for a diagnosis of IgE mediated food allergy, only some people with food 
sensitisation will go on to develop food allergy (WHO and INFOSAN, 2006). 
It is estimated that 1-10% of people suffer from a food allergy worldwide (Rona et al., 2007). 
When the prevalence of common food allergies was investigated in Europe, lifetime 
prevalence was found to be; 0.33-6% for cow’s milk, 0.23- 3.61% for egg allergy, wheat allergy, 
0.26-3.16% soy allergy, 0.22- 8.58% for peanut allergy, 0.45-1.32% for tree nut allergy, 0.62- 
2.17% for fish allergy and 0.70-1.31% for shellfish allergies (Nwaru et al., 2014). Food allergy 
prevalence was determined differently using self-reporting, OFC, SPT or specific IgE testing 
(Nwaru et al., 2014).The prevalence of some food allergies is higher in children compared to 
adults. A meta-analysis found that children less than a year old had cow’s milk and egg allergy 
prevalence of 2% and 0.71% respectively compared to 0.61% and 0.23% in adults (Nwaru et 
al., 2014).  
The prevalence of food allergies has been increasing over time (Kulis et al., 2015). In China, a 
developing country, the prevalence of food allergy increased from 3.1% in 1999 to 7.7% in 
2009 (p = 0.017) in 0- 24 month old children tested through oral food challenges (Hu et al., 
2010). Similarly, the prevalence of “food allergy” as a discharge diagnosis in hospitalised 
patients, in the USA, has increased significantly (p < 0.001) over time from periods 1998 and 
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2000 to 2001 and 2003 to 2004 and 2006 (Branum and Lukacs, 2009). Additionally, data from 
the National Health Survey in the USA, indicated an increasing trend (P=0.01) in self-reported 
food allergy between 1997 and 2007 (Branum and Lukacs, 2009). In Australia, a similar trend 
was observed, where food induced anaphylaxis admissions increased between 1994 and 2004 
(P<0.001) (Liew et al., 2009). 
Atopy 
Atopy is the familial or personal tendency to develop IgE antibodies in response to innocuous 
environmental antigens and to elicit allergic symptoms such as atopic dermatitis, allergic 
rhinitis, asthma and food allergy (Kulis et al., 2015, Daschner et al., 2008, Valenta et al., 2015). 
There is therefore a strong link between food allergy and asthma, allergic rhinitis and eczema. 
Atopy is a risk factor for food allergies and the presence of eczema confers additional risk 
(Gray et al., 2014).  A cohort study carried out in Paris indicated that 6% of infants who had 
atopic dermatitis were sensitised ( 0.35 kU/l of specific IgE) to at least one of the following 
foods; cow’s milk, hen’s egg, peanut, soy, fish, and wheat (Just et al., 2014). Although this 
doesn’t indicate a causal association, it does indicate that in infants with atopy, food 
sensitization frequently co-occurs. Furthermore, a Japanese study found that the risk of 
wheezing, eczema and rhinoconjunctivitis occurring in the last 12 months, increased by 12.8 
to 71.4 times in primary school children who had self-reported food allergies for egg, cow’s 
milk, wheat and crab, compared to those who didn’t (Kurosaka et al., 2011). Self-reported 
allergies data was collected through completion of the International Study on Asthma and 
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Hygiene hypothesis 
The hygiene hypothesis is based on the thinking that a lack of early childhood exposure to 
microbes and infections in the modern era has increased the risk of allergies (Obihara and 
Bardin, 2008). The hygiene hypothesis was first raised by Strachan who noted that larger 
numbers of older siblings seemed to be protective against the acquisition of allergic rhinitis 
(Strachan, 1989). Although some have discounted the hygiene hypothesis (Brooks et al., 
2013), there is recent evidence that credits this theory in understanding allergies (Liu, 2015). 
At a molecular level, T- helper 1 and 2 balance may explain the hygiene hypothesis.  
The T-cell mediated immune response is part of the adaptive immune reaction in human 
beings (Murphy, 2012). When a naïve T-cell encounters an antigen on an antigen presenting 
cell, it proliferates and differentiates into effector cells known as T-helper (TH), TH1, TH2, 
TH17, TH22, regulatory T cells and others depending on the exposures, immune milieu and 
genes (Murphy, 2012, Sompayrac, 2008). These effector cells perform different functions 
(Murphy, 2012). TH1 is involved in cell mediated immunity and inflammation against 
intracellular pathogens (Figure B1) (Murphy, 2012, Sompayrac, 2008). TH2 is involved in 
promoting antibody mediated immunity against parasites (Figure B1) (Sompayrac, 2008, 
Murphy, 2012). An inappropriate TH1 response causes autoimmunity, and an inappropriate 
TH2 immune response is associated with an increased risk of allergies (Murphy, 2012).  
In atopic individuals when the body encounters an allergen, it activates the TH2 which induces 
an allergen specific T-cell and B-cell memory response through cytokines, interleukin 4, 5, and 
13 (Sompayrac, 2008, Valenta et al., 2015).  At this stage sensitisation has occurred, but 
counter-regulatory mechanisms may prevent the person from exhibiting symptoms on future 
exposure (Murphy, 2012). If regulatory mechanisms fail, subsequent exposure will lead to 
symptoms (Murphy, 2012). If that is the case, the allergen cross links with an IgE bound on a 
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mast cell leading to mast cells releasing granules which results in allergic inflammation 
(Sompayrac, 2008).  









Reduced exposure to infections and lower microbial diversity of the microbiome in humans 
leads to a decreased TH1 response and fosters a predominant TH2 type response in the body 
(Matheson et al., 2010). However, a downregulation of TH1 and upregulation of TH2 does not 
explain why there has been an increase in autoimmunity and inflammatory bowel diseases 
which are TH1 mediated with an increase in the prevalence of allergic disorders (Rook and 
Brunet, 2005). Rook and Brunet, (2005) commented that the balance of TH1 and TH2 may not 
be as important as the balance between T-effector cells and T-regulatory cells (Rook and 
Brunet, 2005). Diminished activity of T-regulatory cells may be reason for the increase in both 
allergic disorders (TH2) and autoimmunity and inflammatory bowel diseases (TH1) (Rook and 
Brunet, 2005). Decreased exposure to nonvirulent microorganisms such as helminths and 
lactobacilli leads to decreased activity of T- regulatory cells which are involved in inhibiting 
allergic disorders (Rook and Brunet, 2005). Therefore these type of organisms have been 
coined “old friends” and hence the “old friends hypothesis” has been used to explain the 
mechanism behind the hygiene hypothesis (Rook and Brunet, 2005).  
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Studies investigating the relationship between immunisation and atopic disorders exist, 
however, there are few studies that have investigated the relationship between immunisation 
and food allergy. On one hand, immunisations may increase the risk of allergies through 
protecting against infections or by exposing the individual to the vaccine adjuvants which may 
encourage a TH2 pathway (Matheson et al., 2010). On the other hand, exposure to the 
antigen incorporated in a vaccine may stimulate the TH1 type immune response and 
therefore, result in immunisation protecting against allergies (Rottem and Shoenfeld, 2004).  
In light of this, the objectives of this literature review are as follows;  
Objectives  
1. To examine existing evidence for associations between vaccines and food allergies 
and sensitisation. 
2. To examine existing evidence for associations between vaccines and atopy including; 
asthma, eczema (atopic dermatitis), rhinoconjunctivitis (hay fever). 
Literature Search strategy 
Two databases, Medline and Scopus were used to search for articles related to vaccines, 
food allergies and atopies. The search terms used to conduct the literature search are 
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Table B1: Search terms and returned hits 
MEDLINE SEARCH ON PUBMED results 
(((((((((((vaccines) OR vaccines) OR vaccination) OR vaccinations) OR immunization) OR 
immunizations) OR immunisation) OR immunisations)) OR ((("Vaccination"[Mesh])) OR 
"Vaccines"[Mesh]))) AND ((((((((food allergies) OR food allergy) OR food sensitivity) OR food 
sensitization) OR food sensitisation) OR food hypersensitivity)) OR "Food Hypersensitivity"[Mesh]) 
 
1267 
 (((((((((Vaccination) OR Vaccinations) OR Vaccine) OR Vaccines) OR Immunisation) OR 
Immunisations) OR Immunization) OR Immunizations)) AND (((((((((((Atopy) OR Atopies) OR 
atopic) OR atopic dermatitis) OR eczema) OR allergic rhinitis) OR hay fever) OR asthma) OR 




( vaccination  OR  vaccinations  OR  vaccine  OR  vaccines  OR  immunisation  OR  immunisations  O
R  immunization  OR  immunizations )  AND  ( food  allergies  OR  food  allergy  OR  food  sensitizati
on  OR  food  sensitizations  OR  food  sensitisation  OR  food  sensitisations  OR  atopy  OR  atopies
  OR  atopic  OR  allergies  OR  allergy  OR  atopic  dermatitis  OR  eczema  OR  allergic  rhinitis  OR  
hay  fever  OR  rhinoconjunctivitis  OR  asthma )  AND  ( EXCLUDE ( DOCTYPE ,  "ch" )  OR  EXCLUDE
 ( DOCTYPE ,  "bk" )  OR  EXCLUDE ( DOCTYPE ,  "ed" ) )  
2418 
 
Following the literature search the articles were then sorted according to the articles that had 
the search terms in the title and abstract. The titles of the first 100 articles were scanned for 
each search. If the title indicated that the study looked at the relationship between vaccines 
and allergies, the abstract was assessed to determine if the article contained the appropriate 
information. The first 100 were searched because the relevant literature was displayed in the 
first 50 articles within each search, by the 75th article the papers required for this literature 
review were no longer being picked up by the search engines. Only English articles that looked 
at vaccinations that are administered in the public health system in South African to children 
up until 18 months were considered (OPV, BCG, RV, PCV, DTaP-IPV/Hib, DTaP-IPV-Hib-HBV 
and measles). Further, only experiments that were carried out in humans were considered 
when the abstracts were being reviewed.  A restriction of articles within the last five years 
was placed on the second article search carried out on Medline through PubMed due to a 
high number of articles returned. The search on Scopus excluded book chapters, books and 
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editorials. In addition, the bibliography of articles were searched to ensure that key articles 
in the field were included in the literature review. Articles that information was drawn from 
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Table B2: Summary of articles included in the literature review 







Children 3-14 yrs 
N = 400 
Documented 
BCG 
Atopy (SPT) OR 0.19  (0.06- 0.59) 





4 databases 17 articles 
children aged 17 
years or less 
BCG Asthma OR 0.73  (0.56-0.95 
Sensitization to common allergens 
(IgE) 
OR 1.31  (1.07-1.60) 
Sensitization to common allergens 
(SPT) 
OR 0.87  (0.67–1.13) 
Eczema OR 0.84  (0.64-1.09) 
Rhinoconjunctivitis OR 1.07  (0.89- 1.28) 





Netherlands children attending 
orthodox reformed 
(Protestant) primary 
schools 8–12 yr  
n = 1 872 
DTaP-IPV Food allergy OR 1.13  (0.71–1.81) 
Asthma OR 1.04  (0.76–1.42) 
Hay fever OR 0.79  (0.55–1.12) 
Eczema OR 0.87  (0.66–1.14) 





Netherlands children attending 
orthodox reformed 
(Protestant) primary 
schools 8–12 yr  
n = 1 201 
Hib Food allergy OR 0.68  (0.38–1.19) 
Asthma OR 0.89  (0.55–1.43) 
Hay fever OR 0.94  (0.47–1.90) 
Eczema OR 1.09  (0.75–1.58) 








2, 4, 6 and 
12 to 15 months  
37 868 children 
Selected outpatient 
clinic visit categories 
3 days from vaccine 
PCV Allergic reactions 
 
P = 0.677  
PCV asthma, wheezing, shortness of 
breath, or breath holding 
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13- 14 yrs 
N = 2213 
BCG 
revaccination 
asthma OR 0.68  (0.37- 1.25) 
allergic rhinitis and/or atopic 
eczema 





Poland 6-44 year olds 
 N= 18617 
Measles Symptomatic asthma  OR  0.80  (0.71–0.91) 
Symptomatic allergic rhinitis  OR  1.21  (1.06–1.34)  













vaccination < 1 
yr 
Wheeze, hay fever, eczema 







Wheeze, hay fever, eczema 
Asthma, common allergens  
 
P>0.05 
Flexural eczema on skin 
examination 







Children 5 -13 yrs 











Rhinoconjunctivitis symptoms OR 1.43  (1.04-1.96) 
Doctor’s diagnosis of 
rhinoconjunctivitis 
OR 1.58  (1.05-2.38) 
Overall allergic risk (doctor’s diagnosis of 
rhinoconjunctivitis, and/or asthma, and/or atopic 
eczema) 
OR 0.88  (0.72-1.07) 
 
Wheezing OR 0.75 (0.55-1.02) 
Doctor’s diagnosis of asthma OR 0.77 (0.57-1.03) 
Current atopic eczema symptoms OR 0.89 (0.69-1.16) 
Doctor’s diagnosis of atopic eczema OR 0.81 (0.62-1.06) 









and Australia  
Infants 1–2 yrs 
n = 2184 
polio  Food sensitisation OR 2.60  (1.08–6.25) 
hepatitis B elevated total IgE OR 1.48  (1.03–2.13) 
pneumococci Elevated total IgE OR 0.49  (0.27–0.92) 
polio eczema severity OR 0.66  (0.45–0.97) 
pertussis eczema severity OR 0.30  (0.10–0.89) 
measles eczema severity OR 0.63  (0.49–0.80) 
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Australia HealthNuts cohort 
12 month old infants 
N = 4 433 
DTaP food allergy OR 0.77 (0.36–1.62) 








infants followed up 
for 3- 9 yrs 
early and 
delayed BCG 
atopy OR 0.71  (0.34–1.47) 




rct South Africa 
(non HIV + 
children) 
6, 10, and 14 wks of 
age 19,922 children 
cases 19,914 
controls 




PCV Asthma and Hyperactive-airway 
Disease (59 vaccine recipients and 
33 controls) 
RR 1.79 p = 0.009 
PCV Multiple episodes of asthma  
(22 cases among vaccine recipients, 
as compared with 12 among 
controls) 
 
RR 1.83 p = 0.12 
PCV Children 12 months 
of age  
Asthma and Hyperactive-airway (42 
vs. 22 cases) 
 















Follow up ~13-17 yrs 
n = 1608 
BCG wheezing  RR 1.05  (0.94-1.19) 
hay fever/ eczema RR 0.97  (0.89-1.06) 
Meta-analysis 
BCG 
Asthma RR 0.95  (0.89-1.00) 
Sensitization to common allergens 
(IgE) 
OR 1.05  (0.65-1.69) 
Sensitization to common allergens 
skin prick test (SPT) 
OR 0.93  ( 0.83-1.04) 
Eczema OR 0.85  ( 0.68-1.08) 
Rhinoconjunctivitis OR 1.06  (0.91-1.23) 
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Author Study design Setting Population Vaccine Allery or atopy Measure of Association 
Matheson 2010 Prospective 
cohort  
Tasmania TAHS 
Adults 44yrs  
n = 5729 
diphtheria Food allergy RR 1.09 (0.81, 1.47) 
tetanus RR 1.03 (0.78; 1.35) 
Pertussis RR 1.11 (0.84; 1.47) 
Polio RR 1.11 (0.80; 1.53) 





Eczema, asthma, hay fever P> 0.05 
McKeever  
2004 
Cross section United 
Kingdom 
Children 0- 11 yrs 
n= 29 238  
DPPT asthma HR 10.33  (5.36- 19.91) 
DPPT eczema HR 7.51  (5.27- 10.70) 
MMR asthma HR 2.20  (1.50, 3.21) 





Tasmania Children born 1961 
N = 8443 
Follow up 
at 7, 13 and 30 yrs 
Diphtheria Food allergy by age 7 years OR1.47 (1.04 to 2.07) 
Tetanus Food allergy by age 7 years OR 1.26 (0.93 to 1.71) 
Pertussis Food allergy by age 7 years OR 1.39 (1.01 to 1.91) 
Polio Food allergy by age 7 years OR 1.44 (1.00 to 2.07) 
Diphtheria Asthma by age 7 years OR 1.31  1.33 (1.06 to 1.68) 
Diphtheria Eczema by age 7 years OR 1.53 (1.13 to 2.07) 
Tetanus Eczema by age 7 years OR 1.53 (1.15 to 2.04) 





Korean  adults 18-86 yrs 
n = 200 
BCG scar 38 unspecified common allergens  P>0.05 
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North India children 7–14 yrs 
n = 10,028 
 
 
BCG Sensitisation  
 










Denmark birth cohort followed 
up at 5, 13 & 15 yrs 
 
 
MMR 5yrs asthma  OR 0.32  (0.10; 1.05) 
13yr asthma ever  OR 0.16  (0.05; 0.53) 
13yrs rhinoconjunctivitis ever OR 0.63  (0.14; 2.71) 
13yrs eczema ever  OR 0.46  (0.14; 1.52) 





Sweden Adolescents 15 yrs  
80 000 vaccinated 
98 475 unvaccinated 
DTaP/DTP asthma medication use OR 0.99  (0.95–1.03) 
asthma anti-inflammatory 
treatment 










n = 12 876 
Pertussis atopic dermatitis OR 0.60  (0.37-0.99) 
measles OR 0.79 (0.49–1.28)  
diphtheria OR 0.72 (0.44–1.18) 
BCG OR 0.81 (0.51–1.28) 
tetanus OR 0.98 (0.65–1.47) 
polio OR 0.76 (0.47–1.25) 
OR: odds ratio, SPT: skin prick test, wks: weeks yr: year, DTaP-IPV/Hib: Diphtheria–tetanus–acellular pertussis / Haemophilus Influenza Type b, DTaP: Diphtheria–tetanus–
acellular pertussis, DTP: Diphtheria tetanus pertussis, BCG: bacillus calmette guerin, PCV: pneumococcal conjugate vaccine, MMR: measles mumps and rubella, Hib: 
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Summary and interpretation of literature 
Immunisation and allergy 
 
BCG (Bacillus Calmette–Guerin) 
Negative association: BCG and allergies 
An inverse relationship between the Mycobacterium Tuberculosis Bacillus Calmette–Guerin 
(BCG) vaccine and atopic diseases has been identified in studies carried out in different parts 
of the world (Obihara and Bardin, 2008). In Guinea Bissau, 3-14 year old children who had a 
BCG vaccination scar or documentation confirming a BCG vaccination had a negative 
association (OR 0.19; 95% CI: 0.06 - 0.59) with sensitisation to house dust mites and cockroach 
mix (any SPT wheel 2) compared to those who hadn’t had a BCG vaccination in a sample of 
394 (Aaby et al., 2000).  
 
Similarly, an additional study carried out in the same region showed that in 273 children, 
those who were BCG vaccinated and developed a scar (85%) had a 58% (OR 0.42; 95% CI: 
0.19–0.94) decrease in odds of sensitisation (any SPT wheel 3mm to egg white, peanuts, 
cow’s milk, house dust mites or cockroach) compared to those who were vaccinated and 
didn’t develop a scar (Kiraly et al., 2013). The same study found that the time of BCG 
vaccination, early or delayed, was not significantly associated with sensitization to egg white, 
peanuts, cow’s milk, house dust mites or cockroach and symptoms of atopic disease (Kiraly et 
al., 2013). In the study by Kiraly et al., (2013), BCG vaccination was administered in infancy 
and the researchers tested atopic symptoms and sensitization outcomes 3- 7 years later 
(Kiraly et al., 2013). The vaccinated group that didn’t develop a scar may have had other 
factors that led to a larger prevalence of atopy compared to those who developed a scar, 
thereby confounding the relationship between BCG scar and the negative association with 
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atopy. Nevertheless, the above Guinea Bissau studies by Aaby et al. (2000) and Kiraly et al. 
(2013) indicate that BCG may be protective for atopy in African populations.  
 
An inverse relationship between the BCG vaccine and atopic diseases has been identified in 
studies carried out in Asia. Amongst children between 7-14 years in India, BCG was negatively 
associated (OR 0.76; 95% CI: 0.59-0.98) with sensitisation to apple, wheat, cow milk, hen’s 
egg, peanut, grass, cockroach, house-dust mite and dog dander (skin prick test wheal  3mm) 
(Singh et al., 2013). DTaP, Polio and measles vaccinations were not significantly (P>0.05) 
associated with sensitisation in this cohort (Singh et al., 2013). This study indicates that BCG 
immunisation may be protective for food and aeroallergen sensitisation in Asian populations.  
In Korean adults, between ages 18-86 years, a BCG scar was not significantly (P0.05) 
associated with sensitisation to 38 unspecified common allergens tested through SPTs (Park 
et al., 2015). However, a BCG scar was found to be inversely associated (OR 0.33; 95% CI: 0.14, 
0.77) with asthma confirmed through bronchodilator reversibility or airway hyper 
responsiveness and symptoms (Park et al., 2015). It is likely that the participants in the Park 
et al. (2015) study, had received other childhood vaccinations besides BCG. It is possible that 
BCG and other vaccines may have resulted in the negative association identified. Overall, the 
studies above provide evidence that BCG may be protective for food and respiratory allergy.  
 
Positive association: BCG and allergies 
Children who were BCG vaccinated after the first year of life were more likely to experience 
flexural eczema on their skin compared to those not vaccinated (OR 1.82 95% CI: 1.14–2.91) 
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Insignificant association: BCG and allergies 
Contrastingly, in 2014, a prospective cohort study investigated the effect of BCG vaccination 
on self-reported wheezing and hay fever and or eczema in adolescents between ages 13- 17 
years (Linehan et al., 2014). No significant association was found in this cohort of 1608 
individuals (Linehan et al., 2014). The authors noted an association in a subset of the cohort 
at 7-11 years, showing the effect of BCG maybe temporary (Linehan et al., 2014). This same 
study included an update to a systematic review and meta-analysis which consisted of 22 non 
experimental epidemiological studies (Linehan et al., 2014). From the meta-analysis the 
authors found a (non-significant) lower prevalence of asthma (OR 0.95; 95% CI: 0.89-1), 
eczema (OR 0.85; 95% CI; 0.68-1.08) and allergy in general (OR 0.94; 95% CI: 0.83-1.07) for 
those who were BCG vaccinated compared to those who were not (Linehan et al., 2014). The 
prevalence of rhinoconjunctivitis (OR 1.06; 95% CI, 0.91-1.23) and sensitization to common 
allergies tested by IgE blood tests (OR 1.05; 95% CI: 0.65-1.69) was higher and statistically 
insignificant in BCG vaccinated subjects. (Linehan et al., 2014). However the prevalence to 
common allergies when tested through SPTs was lower and insignificant (OR 0.93; 95% CI: 
0.83-1.04) (Linehan et al., 2014). The study highlights the importance of the outcome measure 
used for diagnosing “allergies” or “atopy” and how this can affect estimates.  
 
A Brazilian study sought to investigate whether a second BCG vaccination administered 7- 10 
years after the neonatal one would be associated with self-reported asthma (de Andrade et 
al., 2013). A sample of 2213 were BCG vaccinated 7- 10 years after a neonatal vaccine and 
followed up for 3- 8 years to assess asthma through the ISAAC questionnaire (de Andrade et 
al., 2013). The study found no significant association between BCG revaccination and disease 
outcomes (de Andrade et al., 2013). Different results, negative or lack of association, from 
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different studies looking at a similar association indicate the importance of carrying out 
further research that will add towards reaching definitive conclusions. 
 
DTaP/DTP (Diphtheria, Tetanus and Pertussis) & Polio 
Positive association: DTP and allergies 
1501 individuals from Tasmania participated in a retrospective cohort study investigating the 
association between several childhood vaccines and self-reported atopic diseases and self-
reported food allergies (Nakajima et al., 2007). The individuals consisted of children born in 
1961 and the study followed up the participants at 7, 13 and 30 years of age (Nakajima et al., 
2007). The study found that the adjusted association between vaccination and food allergies 
at age 7 was positive for both diphtheria (OR 1.47; 95%CI: 1.04-2.07) and whole pertussis (OR 
1.39; 95%CI: 1.01 -1.91) vaccinations (Nakajima et al., 2007). The association for eczema was 
positive for those vaccinated with diphtheria (OR 1.53; 95%CI: 1.13 to 2.07), tetanus (OR 1.53; 
95%CI: 1.15-2.04) and whole pertussis (OR 1.46; 95%CI: 1.10-1.93) (Nakajima et al., 2007).The 
relative odds ratio for asthma and diphtheria (OR 1.33; 95%CI: 1.06-1.68) vaccinated 
individuals was positive 1.33 (95%CI: 1.06-1.68)   (Nakajima et al., 2007). These associations 
became insignificant after 13 years of follow up except for the association between eczema 
and whole pertussis vaccination, where vaccinated subjects  now had a lower odds ratio for 
eczema (OR 0.57; 95%CI: 0.35-0.93) (Nakajima et al., 2007). Therefore, the age at which 
allergies are assessed in relation to vaccines is important and different effects may be 
dominant at different ages. 
A British study found that the hazards of incident diagnosed asthma (HR 10.33; 95%CI: 5.36- 
19.91) and incident diagnosed eczema (HR 7.51; 95%CI: 5.27- 10.70) in a cohort of 29 238 
children was greater for those who received diphtheria, polio, whole pertussis, and tetanus 
18 
 
Part B Literature Review 
(DPPT) vaccination, when controlling for GP visits (McKeever et al., 2004). A strength of this 
study is the large sample size, 29 238 providing high power, although the associations may 
have been identified with a smaller study, but with less precision. 
 
Negative association: DTP + Polio and allergies 
A negative association between DTP and atopy has been identified in other parts of the world. 
Gruber et al., (2008) carried out an international study that looked at the association between 
13 childhood vaccines (diphtheria, tetanus, whole &acellular pertussis, polio, haemophilus 
influenza Type B, hepatitis B, mumps, measles, rubella, varicella, BCG, meningococci and 
pneumococci) and food allergens in infants between 1-2 years (Gruber et al., 2008). Polio was 
found to have a positive increased effect on food sensitisation (IgE   0.35kU/L to one or more; 
milk, egg and peanut) (OR 2.60 95% CI: 1.08–6.25) (Gruber et al., 2008).  
 
Lastly, an Ethiopian study was carried out, to investigate the effect of lifestyle factors on 
atopic dermatitis (Yemaneberhan et al., 2004). The study, which consisted of 12 876 
individuals, reported whopping cough vaccine to be negatively associated with atopic 
dermatitis (OR 0.60; 95% CI: 0.37-0.99) (Yemaneberhan et al., 2004). However, BCG, measles, 
diphtheria, small pox, mumps tetanus and polio vaccines were not significantly associated 
with self-reported atopic dermatitis and SPT 3mm for dust mites, aspergillus and mixed 
threshing (Yemaneberhan et al., 2004). This study was carried out in Africa and gives insight 
into possible associations that may be found in a South African cohort. 
Insignificant association: DTP or Polio and allergies 
Although some studies have found positive and negative associations between DTP and atopy 
or food allergies, other studies have found no significant association between the variables. 
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A Swedish prospective cohort study, found no significant association between DTP (whole 
and acellular pertussis) immunisation and asthma medication use (OR 0.99 95%CI: 0.95–1.03) 
and asthma anti-inflammatory treatment (OR 0.97 95%CI: 0.92–1.01) (Vogt et al., 2014). This 
study investigated asthma in adolescent participants who were exposed to DTP as infants 
(Vogt et al., 2014). It is possible that there may have been participants who were asthmatic 
but not taking medication and if this was related to vaccine exposure this would have resulted 
in misclassification and incorrect estimates (Vogt et al., 2014). 
 
In another study, of cross sectional design, no significant association was identified between 
those vaccinated with diphtheria, tetanus, acellular pertussis and poliomyelitis (DTaP-IPV) 
vaccination during infancy and questionnaire obtained data on food allergies (OR: 1.13 95% 
CI: 0.71–1.81) or asthma (OR: 1.04 95% CI: 0.76–1.42), eczema (OR: 0.87 95% CI:0.66–1.14) , 
hay fever (OR: 0.79 95% CI: 0.55–1.120) and any atopic disorder (OR: 1.00 95% CI: 0.80–1.24) 
in 8- 12 year olds in the Netherlands (Bernsen et al., 2006a). Although a questionnaire was 
used to collect data on the exposure and outcome variables, the authors did validate a subset 
of the sample with IgE blood tests, improving the validity of the findings. 
 
Similarly, Matheson et al. (2012) carried out a study looking at the association between 
childhood immunisation and any occurrence of self-reported food allergy and atopic disease. 
The authors investigated childhood immunisation status for diphtheria, tetanus, pertussis, 
poliomyelitis and small pox (Matheson et al., 2010). The adjusted risk ratios for food allergy 
when exposed to the following vaccines were insignificant; diphtheria 1.09 (95%CI: 0.81-1.47) 
tetanus 1.03 (95%CI: 0.78-1.35), whole pertussis 1.11 (95%CI: 0.84-1.47), Polio 1.11 (95%CI: 
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0.80-1.53) and DTP 1.02 (95%CI: 0.80-1.30) (Matheson et al., 2010). Furthermore, there were 
no significant associations between any of the vaccines and asthma in the last 12 months or 
ever having had food eczema or hay fever (Matheson et al., 2010). This study was carried out 
on a sample size greater than 5550 individuals increasing the power of the study to find a 
significant association. A questionnaire completed by parents in 1968 before the individuals 
in cohort began school was used to determine exposure to immunisation and a questionnaire 
administered in 2004 was used to determine atopy and food allergy outcomes (Matheson et 
al., 2010). Therefore, recall bias may have occurred in this study. Secondly, the questionnaire 
completed in 2004 was self-administered by participants who were not specifically in the 
medical field (Matheson et al., 2010). Consequently, there is a possibility that outcomes may 
have been completed inaccurately. An advantage of this cohort study is temporality. Exposure 
was assessed and the outcome was measured over time thereafter.  
 
The Australian Healthnuts study is the only study that has investigated the relationship 
between DTaP vaccination and challenge proven food allergies in infants (Kiraly et al., 2016). 
The cross sectional study revealed that there was no association between DTaP vaccination 
and food allergies (Kiraly et al., 2016). However, the study did demonstrate that DTaP 
administered with a month delay was negatively associated with self-reported eczema (OR 
0.57; 0.34- 0.97, p=0.04) in comparison to when the vaccine was administered at the standard 
time (Kiraly et al., 2016). Although this finding may have been due to reverse causation, it 
does raise the possibility that the timing of vaccinations may influence the association with 
atopy. Inconclusive results on the association between DTP and polio vaccinations and atopy 
warrants further research to be carried out.  
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PCV (pneumococcal conjugate vaccine) 
Positive association: PCV and allergies 
The pneumococcal conjugate vaccine (PCV) is positively associated (RR 1.79; p = 0.009) with 
asthma and hyperactive-airways in South African children 31 days after receiving the 
vaccination (Klugman et al., 2003). Similarly, PCV is positively associated (RR = 1.91; p = 0.02) 
with asthma and hyperactive airways in children greater than 12 months of age (Klugman et 
al., 2003). However, no significant association was observed for multiple episodes of asthma 
and PCV in these children (RR 1.83; p = 0.12) (Klugman et al., 2003). In California, PCV was 
found to be non-significantly associated with allergic reactions and asthma (P>0.05) (Black et 
al., 2000).  
 
MMR (Measles Mumps and Rubella) 
Positive association: MMR and allergies 
The MMR vaccine has been found to be positively associated with atopy in different parts of 
Europe. In Poland, Measles was found to be positively associated with both self-reported 
symptomatic rhinitis (OR 1.22; 95%CI: 1.11–1.32) and allergic rhinitis (OR 1.21; 95%CI: 1.06–
1.34) in participants who ranged from 6 and 44 years of age in a cross sectional study (Dulny 
et al., 2015). However, these associations didn’t hold for doctor diagnosed or SPT diagnosed 
atopy (Dulny et al., 2015). In another MMR study, in order to find children who had not 
received an MMR vaccination, children from Steiner schools who were unlikely to be 
vaccinated were participants in the investigation (Floistrup et al., 2006). The study showed 
that MMR was positively associated with rhinoconjunctivitis symptoms (OR: 1.43; 95%CI: 
1.04-1.96) and doctor’s diagnosed rhinoconjunctivitis (OR: 1.58 95%CI: 1.05-2.38) (Floistrup 
et al., 2006). However, no significant association was found between MMR and self-reported 
wheezing (OR: 0.75 95%CI: 0.55-1.02), self-reported eczema (OR: 0.89 95%CI: 0.69-1.16), 
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doctor diagnosed eczema (OR: 0.81 95%CI: 0.62-1.06) and asthma (OR: 0.77 95%CI: 0.57-1.03) 
and atopic sensitisation (IgE level  0.35 kU/L.) (OR: 0.91 95%CI: 0.63-1.31) (Floistrup et al., 
2006).  A weakness of this study is the possibility for confounding as Steiner children may have 
multiple other differing exposures. Similarly, McKeever et al (2004), found that: children with 
MMR vaccination had a significantly increased risk in clinically diagnosed eczema (hazard ratio 
3.50; 95%CI: 2.38- 5.15) and asthma (hazard ratio 2.20; 95%CI: 1.50- 3.21) compared to those 
who were not vaccinated (McKeever et al., 2004). 
 
Negative association: MMR and allergies 
Other studies have shown MMR to be negatively associated with atopy. The study by Dulny 
et al., (2015), reported a negative association between measles vaccination and self-reported 
asthma (OR 0.80, 95%CI: 0.71–0.91) and no significant association regarding doctor diagnosed 
or SPT diagnosed asthma (Dulny et al., 2015). Similarly, in a Faroe islands birth cohort, the 
measles mumps and rubella (MMR) vaccine was found to be significantly associated with a 
reduced odds of 0.16 (95%CI: 0.05-0.53) of asthma 13 year old children (Timmermann et al., 
2015).  MMR is administered at 12 months and 12 years in Denmark and the birth cohort was 
followed up at 5, 13 and 15 years (Timmermann et al., 2015). At 5 years the association with 
asthma was insignificant. This may point to the transient nature of a protective association. 
The follow up included a clinical examination, a health questionnaire completed by the 
mother and medical history check and an interview (Timmermann et al., 2015). The use of a 
range of methods for assessing atopy outcomes in this study makes the results robust.  
 
Hib (Haemophilus Influenza Type b) 
Insignificant association: Hib and allergies 
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A cross sectional study carried out in the Netherlands found that there were no significant 
association between Haemophilus Influenza Type b (Hib) vaccination and patient-reported 
food allergies (OR 0.68 95% CI: 0.38–1.19) or patient reported asthma (OR 0.89 95% CI: 0.55–
1.43), hay fever (OR 0.94 95% CI: 0.47–1.90) and eczema (OR 1.09 95% CI: 0.75–1.58) in in 
1201 participants between 8-12 years of age (Bernsen et al., 2006b).  
 
Conclusion 
Associations at different ages 
The articles above indicate that different studies carried out in different parts of the world 
result in different types of association between vaccines and food allergies and atopic 
diseases. Furthermore, the association and strength of association may differ depending on 
the age that the association is investigated. For example, the study by Nakajima et al (2007), 
showed that pertussis vaccination was positively associated (OR 1.46; 95%CI: 1.10-1.93) with 
eczema with 7 year olds and then negatively associated (OR 0.57; 95%CI: 0.35 to 0.93) with 
eczema with 13 year olds (Nakajima et al., 2007). Similarly, the study by Linehan et al., (2014) 
and Timmermann et al., (2015) displays this transient nature. Further, some studies 
investigated the association between vaccinations and atopic diseases in a wide age range of 
participants. Examples of these studies include the studies looking at the relationship 
between BCG and atopy in 3-14 year olds (Aaby et al., 2000) olds and 7-14 year olds (Singh et 
al., 2013) or 18- 86 year olds (Park et al., 2015). If the association is sensitive to age then the 
effect of vaccines on atopy may not be seen at all ages.    
 
Measuring outcome 
Studies looking at the same vaccination with different results may have been influenced by 
the way the outcome was assessed. If the outcome was assessed through a questionnaire as 
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opposed to physical examination or food challenge testing then recall bias might have 
influenced the estimates.  Food allergy has been found to be overestimated in self-reported 
instances (Rona et al., 2007). Further, some physical examinations involved physical 
inspection, food challenge testing, SPTs or IgE blood measures. Depending on the robustness 
of the measure used to estimate the outcome this would affect the validity of the associations 
found. In addition, exposure to vaccines, was determined in different ways and might have 
influenced the validity of the associations. Immunisation was assessed through recall, 
checking medical records or assessing a scar. Using medical records and scars is more reliable 
than recall.  Finally, it is possible that vaccinations may affect different aspects of atopy 
differently. Moreover, the same vaccine, such as Pertussis, constituted differently, whole or 
acellular, may affect atopy differently. 
 
Effect size 
It is important to determine whether there is a negative or positive effect of immunisation on 
food allergies or atopic diseases, and additionally the effect size of the associations. Many of 
the significant associations found in the articles described above are small. The associations 
that indicate a positive association for atopy or food allergies in the articles above have 
relative odds ratios which are less than 2 and greater than 0.3 for negative effects. In addition, 
the precision of the effects is important. The smaller a sample size the less precise the 
estimate. 
The articles above indicate that vaccinations may be positively or negatively associated with 
food allergies. Investigating this phenomenon in a South African cohort will provide insight 
into modifiable factors that influence food allergy in South African children.  
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Abstract 
Background 
The prevalence of food allergy is higher in children than adults and is increasing. The effect of 
vaccinations on prevalence of food allergy and food sensitisation is not clear.  
Objective 
To determine if a relationship exists between vaccinations and food allergy and food 
sensitisation in children in the first 18 months of life who live in urban and rural South African 
communities. 
Methods 
A food allergy and sensitisation survey was conducted in unselected children between 12 and 
36 months of age in urban Cape Town and the Mqanduli district of the Eastern Cape. Food 
sensitisation and allergy were determined through skin prick tests (SPT) and oral food 
challenges respectively. We examined the association between self-reported immunisation 
status and food sensitisation and food allergy in children using multivariate logistic regression. 
Children less than 18 months were excluded from analysis for vaccines offered at 18 months. 
 Results 
Among 708 urban and 400 rural children, the numbers of participants positive for food 
sensitisation and allergy, eczema, hay fever and asthma were significantly greater in the urban 
sample compared to the rural sample (p<0.05). Further, in 708 urban children, those who had 
a BCG vaccine at birth were 0.05 (OR 0.05; 95% CI: 0.004- 0.6) times less likely to have an SPT 
 7mm. There were no other significant associations between childhood vaccinations and 
food sensitization at SPT 1mm, 3mm and 7mm. There was no significant association 
between vaccinations and food allergy. 
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Conclusion 
In conclusion, there was very little evidence of an association between BCG vaccination in 
children and food allergic sensitisation or food allergy. However, in a small subgroup, there 
was evidence in an association between BCG and SPT 7 mm. 
 
Key Words 
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Introduction 
It is estimated that 1-10% of people suffer from a food allergy worldwide (1). The prevalence 
of some food allergies is higher in children compared to adults. A meta-analysis found that 
children less than a year old had cow’s milk and egg allergy prevalence of 2% and 0.71% 
respectively compared to 0.61% and 0.23% in adults (2). Food allergy was determined through 
self-reporting, OFC, SPT or specific IgE testing (2). Further, the prevalence of food allergies 
has been increasing over time (3, 4). The prevalence of “food allergy” as a discharge diagnosis 
in hospitalised patients, in the USA, was found to increase significantly (p < 0.001) over time 
from periods 1998 and 2000 to 2001 and 2003 to 2004 and 2006 (5).  
 
The prevalence of food allergies amongst children in South Africa is not well described. One 
study reported food allergy prevalence amongst children between 6 months and 10 years 
with atopic dermatitis, a risk factor for food allergies, to be 40% through oral food challenge 
(OFC) tests (6).  Recently, results were published indicating a prevalence of food sensitization 
(indicated by a skin prick test (SPT) 1mm) of 12.3% and food allergy of 2.5% amongst 512 
unselected urban Cape Town children between 12 and 36 months of age (7). The study 
reported a prevalence of food allergies (confirmed through an oral food allergy test) to be 
1.8%, 0.2%, 1.2% and 0.2% for egg, cow’s milk, peanut, and fish respectively (7).  
 
In line with the hygiene hypothesis (8), vaccinations may contribute towards reduced 
exposure to infections leading to a predominant allergen specific response in the body (9) or, 
exposure to the virus or microbe in the vaccine may decrease the risk for allergy (10).  In 
Guinea Bissau, children who had a  Bacillus Calmette Guérin (BCG) vaccination scar were less 
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likely to have sensitisation (any SPT wheel  3mm to egg white, peanuts, cow’s milk, house 
dust mites or cockroach) compared to those who were vaccinated and didn’t develop a scar 
(OR 0.42; 95% CI: 0.19 - 0.94) (11). Similarly, In India, BCG was protective for sensitisation to 
apple, wheat, cow milk, hen’s egg, peanut, grass, cockroach, house-dust mite and dog dander 
collectively (OR 0.76; 95% CI: 0.59-0.98) (SPT wheel  3mm) (12). In contrast the Polio vaccine, 
was found to increase the risk for food sensitisation in children between 1 and 2 years of age 
(13). Yet other vaccines, Diphtheria–tetanus–pertussis (DTP) and Haemophilus Influenza Type 
b (Hib), were found to not be associated with food allergy in different parts of the world (9, 
14-16). 
 
There have been no previous studies looking at the association between food sensitisation 
and food allergy in South Africa. Determining if associations between vaccinations and food 
sensitisation and allergy exist will provide insight into the factors associated with food allergy.  
As a part of the South African Food sensitisation and Food Allergy (SAFFA) study, the aim of 
this study is to determine if a relationship exists between vaccinations and food allergy and 
food sensitisation in children in the first 18 months of life who live in urban Cape Town and in 
rural Mqanduli in the Eastern Cape. 
Methods 
Secondary data analysis of an observational cross sectional study was carried out to 
determine whether an association between vaccinations and food sensitisation and allergy 
existed. Participant data was attained from the database of the SAFFA study. 1739 eligible 
children, 12-36 months of age from registered crèches in metropolitan Cape Town and from 
communities surrounding health centres in Mqanduli, were recruited for the SAFFA study. 
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Parents and guardians of eligible participants were invited to participate in the study and 
provided with information pertaining to the study and thereafter, informed consent was 
obtained. Demographic data and other information pertaining to participant’s background 
was acquired through administering a questionnaire to parents and guardians. 
Vaccine measures 
The vaccination schedule during the time of data gathering is described in Table C1. 
Table C1: South Africa vaccine schedule at time of study 
Time Vaccination Time Vaccination 
Birth BCG 14 weeks RV(2)  
 OPV (0) DTaPIPV/HiB(3)  
6 weeks OPV (1)  HBV(3)  
RV (1)  PCV7 or 13 (2)  
DTaPIPV/HiB (1)  9 months Measles vaccine  
HBV (1)  PCV 7 or 13 (3)  
PCV7 or 13(1)  18 months DTaPIPV/HiB (4) 
10 weeks DTaPIPV/HiB (2)  Measles Vaccine 
HBV (2)    
 
Participants in this study were a minimum of 12 months and a maximum of 36 months, 
therefore the sample number used to investigate an association with the fourth DTaP-IPV/Hib 
vaccine and measles vaccine and study outcomes is smaller than the sample number used to 
investigate the associations of the other 15 vaccines. Vaccine status was ascertained through 
questionnaire and confirmed through immunisation records if they were available. 
Allergy outcome measures  
Each child was tested for food sensitization by means of a skin prick test to the following 
foods; hen’s egg, cow’s milk, soy, wheat, fish, peanut and hazelnut. A participant was 
classified as food sensitised if the result of the SPT was greater than 1mm after subtracting 
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the size of reaction to the negative controls, and categorised using thresholds greater than 
1mm or 3mm or 7mm (8). If a participant was found to have a SPT result greater than 1mm 
and was not ingesting and “tolerant” to a full age-appropriate portion, they were invited to 
attend an oral food challenge test which was carried out for the particular food they were 
sensitised to. A participant was categorised as food allergic if found oral food challenge 
positive to at least one of the foods they were tested for. Self-reported information on 
asthma, hay fever and eczema was collected using the following questions; asthma- “has your 
child ever had symptoms of asthma without having a cold or chest infection? e.g. wheeze, 
persistent cough at night or when exercising, shortness of breath”, hay fever- “Has your child 
ever had symptoms of hay fever? e.g. itchy runny eyes, itchy runny nose, blocked nose, 
frequent sneezing without having a “cold” or upper respiratory tract infection?” Eczema- “Has 
your child ever had symptoms of eczema? e.g. an itchy rash especially in the folds of the 
elbows, behinds the knees, in front of the ankles, under the buttocks or around the neck, ears 
or eyes” Appendix 4. These questions are derived from ISAAC studies and have been used in 
local studies (17). 
Statistical analysis 
Participant demographics and comparison of the pattern of immunisation coverage in the 
rural and urban sites was done using descriptive statistics, chi squared test and wilcoxon rank 
sum test. We used chi squared tests and logistic regression to investigate univariate 
associations between immunisation and food allergy and food sensitisation and between 
immunisation and self-reported asthma, hay fever and eczema. As coverage of many vaccines 
was 100% in rural areas, we were unable to assess the association between these vaccines 
and the different outcomes for this area, hence we conducted the analysis separately for 
urban and rural areas. Similarly, since very few children in the rural area had food allergy, we 
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did not examine associations between vaccines and food allergy for rural children. 
Multivariate logistic regression was used to investigate associations between vaccines and 
the different outcomes adjusting a priori for potential confounders of age at enrolment, 
gender, breast feeding, number of older children in the house and clinically diagnosed 
eczema. A 95% confidence interval was used to determine significance. All statistical analyses 
were conducted using Stata 12 (18) 
Ethics 
Ethical clearance to carry out this study was granted by the Human Research Ethics 




Of 1739 eligible children recruited into the study, 1160 responded to the invitation to 
participate in the study and 1114 actually participated in the study. There were, 1 108 
participants who completed the questionnaire and SPT tests; 708 were from urban Cape 
Town and 400 from rural Mqanduli in the Eastern Cape (Figure C1). Immunisation coverage 
in the rural participants is greater than that of the urban participants up until vaccines offered 
from 9 month onwards, however, none of these difference are significantly different (P0.05) 
(Table C2). The proportion of food sensitised and food allergic participants is significantly 
greater in the urban sample compared to the rural sample (p<0.05) (Table C2). Similarly, atopy 
outcomes are significantly higher in the urban group compared to the rural group (p<0.05) 
(Table C2). The age at enrolment and the number of older siblings is higher in the urban group 
(p<0.05) (Table C2).  
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Table C2: Characteristics of study population 
Characteristics  % Urban (n)  
Total n =708 
% Rural (n)  
Total n =400 
P 
value 
Immunization status Positive Positive  
Birth    
BCG 99.6  (705) 100  0.192 
OPV(0) 99.2  (702) 100 0.065 
6 weeks    
OPV(1) 99.4  (704) 99.7  (399) 0.452 
RV (1) 99.7  (706) 100   0.287 
DTaP-IPV/Hib (1) 99.7  (706) 100 0.287 
HBV(1) 99.7  (706) 100 0.287 
PCV(1) 99.7  (706) 100 0.287 
10 weeks    
DTaP-IPV/Hib (2)  99.6  (705) 100 0.192 
HBV(2) 99.6  (705) 100 0.192 
14 weeks    
RV (2) 99.3  (703) 100 0.092 
DTaP-IPV/Hib (3)  99.4  (704) 100 0.132 
HBV(3) 99.6  (705) 100 0.192 
PCV(2) 99.6  (705) 99.8  (399) 0.643 
9 months    
MV(1) 98.5  (697) 97.3  (389) 0.170 
PCV(3) 97.9  (693) 96.3  (385) 0.108 
18 months    
DTaP-IPV/Hib (4)  91.4  (552) 
# n= 604 
89  (250) 
# n= 281 
0.250 
MV2 91.4  (552) 
# n= 604 
89  (250) 
# n= 281 
0.250 
Food sensitisation Positive Positive  
SPT  1mm *  13.4  (94) 5.0  (18) 0.000 
SPT  3mm *  9.8  (69) 3.0  (12) 0.000 
SPT  7mm *  4.2  (30) 2.0  (8) 0.049 
Food allergy Positive Positive  
Oral food challenge *   4.0  (28) 1.0  (4) 0.005 
Atopy Positive Positive  
Self-reported asthma *  11.3  (80) 1.0  (4) 0.000 
Self-reported hay fever *  26.6  (188) 3.3  (13) 0.000 
Self-reported eczema *  24.5  (173) 2.0  (8) 0.000 
Confounders Positive Positive  
Breast feeding  87.7 88.5 0.698 
Clinically diagnosed Eczema *  12.6 0.8 0.000 
Gender  F= 47.0%   F=  43.5%    0.318 
Median age at enrolment (months) *  27      IQR = 21 - 32 21      IQR = 17- 28 0.000 
Median number of older siblings * 1        IQR = 0- 1 2         IQR = 1-3 0.000 
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SPT: skin prick test, DTaP-IPV/Hib: Diphtheria–tetanus–acellular pertussis / Haemophilus Influenza Type b, BCG: 
bacillus calmette guerin, PCV: pneumococcal conjugate vaccine, OPV: oral polio vaccine, MV: measles vaccine, 
HBV: hepatitis B vaccine  
#The total number of these participants is less than the total 708 for urban and 400 for rural participants due to 
some participants being less than 18 months of age and not having received the DTaP-IPV/Hib (4) and mv vaccine 
yet. 
*Significant different between urban and rural for this variable (P<0.05) 
 
Table C3 shows the associations between vaccinations at birth, 9 months and 18 months and 
SPT greater than 1mm, 3mm and 7mm.  There is a significant protective association between 
BCG offered at birth and SPT  7mm (adjusted OR: 0.05 95% CI: 0.004 - 0.6) in the urban 
sample (Table C2). There are no other significant associations between childhood vaccinations 
offered up until 18 months and food sensitization as indicated by SPT greater than 1mm, 3mm 
and 7mm (Table C3 and C4). 
  
Table C3: Associations between immunisation status and SPT  1mm,  3mm and  7mm 
in urban and rural participants 
Outcome  Urban  Rural  
SPT  1mm Vaccine *adjusted OR 95%CI *adjusted OR 95%CI 
Birth BCG  0.2 0.02- 2.7   
 OPV(0) 0.3 0.1- 1.5   
9 months MV(1) 1.8 0.2- 14.9   
 PCV(3) 1.1 0.2- 5.0 0.6 0.1-  5.4 
18 months DTaP-IPV/Hib (4)  0.9 0.4 - 2.4 1.4 0.2- 12.0 
 MV2 0.9 0.4 - 2.4 1.4 0.2- 11.7 
SPT  3mm      
Birth BCG 0.2 0.02- 2.7   
 OPV(0) 0.3 0.1- 1.5   
9 months MV(1) 1.8 0.2- 14.9   
 PCV(3) 1.1 0.2- 5.0   
18 months DTaP-IPV/Hib (4)  0.8 0.3- 2.3   
 MV2 0.8 0.3- 2.3   
SPT  7mm      
Birth BCG 0.05 0.004- 0.6   
 OPV(0) 0.2 0.02- 1.6   
9 months MV(1) 0.5 0.1-  4.6   
 PCV(3) 0.7 0.1- 5.7   
18 months DTaP-IPV/Hib (4)  0.6 0.1- 3.1   
 MV2 0.6 0.1- 3.1   
 SPT: skin prick test, DTaP-IPV/Hib: Diphtheria–tetanus–acellular pertussis / Haemophilus Influenza Type b, BCG: 
bacillus calmette guerin, PCV: pneumococcal conjugate vaccine, OPV: oral polio vaccine, MV: measles vaccine,  
13 
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OR: Odds ratio,   
*odds ratios adjusted for  age at enrolment, gender, breast fed, number of older children in the house and 
clinically diagnosed eczema. 
Where there is a blank in the rural column, there was no difference between exposed and non-exposed in this 
cohort. Therefore, no odds ratio was calculated. 
 
 
Table C4: Association between immunisation status and food allergy in the urban 
participants 
Outcome Vaccine OR 95% CI *adjusted 
OR 
95%CI 
Food allergy      
Birth OPV(0) 0.2 0.02- 1.8 0.1 0.02- 1.3 
9 months PCV(3) 0.6 0.1 – 4.5 0.6 0.1- 5.0 
18 months DTaP-IPV/Hib (4)  0.9 0.2 – 4.1 1.1 0.2- 5.4 
 MV2 0.9 0.2 – 4.1 1.1 0.2- 5.3 
DTaP-IPV/Hib: Diphtheria–tetanus–acellular pertussis / Haemophilus Influenza Type b, PCV: pneumococcal 
conjugate vaccine, OPV: oral polio vaccine, MV: measles vaccine, OR: Odds ratio 
*odds ratios adjusted for  age at enrolment, gender, breast fed, number of older children in the house and 
clinically diagnosed eczema 
 
No significant associations are identified between vaccines and food allergy determined 
through oral food challenges in the urban cohort (Table C4). For atopy outcomes; asthma, hay 
fever and eczema were investigated, and there are no significant association between these 
outcomes and vaccine exposure as shown in table C5 and Appendix 8 and 10.  
Table C5: Association between immunisation status and self-reported eczema, asthma 
and hay fever for urban and rural participants 








Birth OPV(0) 0.5 0.1- 4.6   
6 weeks OPV(1) 0.3 0.03- 3.1   
14  weeks DTaP-IPV/Hib 
(3)  
0.3 0.03- 2.5   
18 months DTaP-IPV/Hib 
(4)  
0.7 0.3- 1.7   
 MV2 0.6 0.2- 1.4   
Self-reported 
Hay fever 
     
Birth OPV(0) 0.7 0.1- 3.7   
6 weeks OPV(1) 0.3 0.1- 2.4   
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14 weeks DTaP-IPV/Hib 
(3)  
0.9 0.1 – 8.8   
9 months MV(1) 1.0 0.3 – 4.0 0.4 0.1- 3.5 
 PCV(3) 1.0 0.3-  3.3 0.5 0.1- 4.0 
18 months DTaP-IPV/Hib 
(4)  
0.6 0.3 - 1.1 0.9 0.1-  8.1 
 MV2 0.7 0.4- 1.3 0.8 0.1- 7.7 
Self-reported 
eczema 
     
Birth OPV(0) 0.6 0.1- 3.4   
6 weeks OPV(1) 1.0 0.1- 10   
14  weeks RV (2) 1.4 0.2- 13   
 DTaP-IPV/Hib 
(3)  
1.0 0.1- 10   
 HBV(3) 0.7 0.1-  7.7   
9 months MV(1) 0.8 0.2 -  3.1 0.2 0.03- 2.4 
 PCV(3) 0.9 0.3 -  2.8 0.3 0.03- 2.9 
18 months DTaP-IPV/Hib 
(4)  
1.2 0.6 - 2.6 0.2 0.02- 2.4 
 MV2 1.4 0.7- 3.1 0.3 0.02- 2.8 
DTaP-IPV/Hib: Diphtheria–tetanus–acellular pertussis / Haemophilus Influenza Type b, PCV: pneumococcal 
conjugate vaccine, OPV: oral polio vaccine, MV: measles vaccine, HBV: hepatitis B vaccine, OR: Odds ratio,   
*odds ratios adjusted for  age at enrolment, gender, breast fed, number of older children in the house and 
clinically diagnosed eczema. Self-reported eczema odds ratio adjusted for age at enrolment, gender, breast fed 
and number of older children in the house. 
Where there is a blank in the rural column, there was no difference between exposed and non-exposed in this 
cohort. Therefore, no odds ratio was calculated. 
  
Discussion 
This is the first time a study of this nature, looking at the association between vaccines and 
food allergy and food sensitisation, has been carried out in South Africa. In this study, those 
children who had a BCG vaccine at birth were found to be 0.05 (95% CI: 0.004 - 0.6) times less 
likely to have an SPT  7mm when confounders were adjusted for. The threshold of SPT 7mm 
and greater for many foods is associated with a high (>95%) probability that the child is truly 
food allergic (19). The number of BCG unvaccinated participants in the study was a total of 
three out of 708 individuals. Of the three, one was positive for sensitisation at an SPT  7mm. 
Therefore, the sample size of the unvaccinated group was inadequate to confirm a valid 
association. In future, a study with a larger unvaccinated (unexposed) group is needed.  
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Few studies that have investigated the effect of BCG vaccination on food sensitisation. BCG 
vaccination has previously been found to decrease the risk for atopy (SPT  2mm or  3mm) 
in other African populations (11, 20), and this protective effect included sensitisation (SPT  
3) to different elements including different foods (11). Further, some studies show a 
protective relationship between BCG and other atopic disorders such as asthma, eczema and 
hay fever (11, 12, 20, 21). An atopic individual develops IgE antibodies and elicits allergic 
symptoms such as atopic dermatitis, allergic rhinitis, asthma and food allergy in response to 
an antigen (3, 22, 23). There is therefore, a strong link between food allergy and these other 
forms of atopy. In Cape Town, South Africa, tuberculosis infection in children, measured 
through a positive tuberculin skin test, was found to be protective for allergic rhinitis (0.43 
95% CI: 0.24–0.79) (10). This study, supports the notion that exposure to microbes decreases 
the risk for allergic diseases, although reverse causation could also have accounted for these 
findings due to children with atopy being more likely to respond more strongly to the 
tuberculin skin test. In our study, exposure to the attenuated BCG antigen through vaccination 
may have decreased the risk of food sensitisation. In support of the protective effect of BCG, 
a study carried out on mice found that neonatal BCG vaccination resulted in inhibition of 
allergen induced airway hyper-responsiveness, eosinophilia and mucus over-production (24) 
and shifted cytokine responses from a predominance of Th2- to Th1-type (24).Therefore, BCG 
vaccination in mice models was found to be protective for asthma. The studies above provide 
evidence that BCG vaccination may be protective for food sensitisation, however, the current 
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Limitations of this study include the low number of unvaccinated individuals resulting in poor 
estimates for the BCG and sensitisation association. Further, no other significant associations 
were identified due to the low number of unvaccinated participants in the study. Therefore, 
it is possible that associations may exist but were undetectable. Secondly, the inability to 
gauge temporality between exposure and outcome due to it being a cross-sectional study. 
Other studies that have found a significant association between BCG vaccination and atopy 
were similarly cross sectional (11, 12, 20, 21).  Therefore, in future, a cohort study may provide 
clarity on temporality. Thirdly, when the initial questionnaire was drawn up, details of the 
time the participant was vaccinated was not sought. Consequently, it was not possible to 
determine whether the participants received their vaccines according to the South African 
vaccine schedule or not and if time of vaccination may be playing a role in the attained odds 
ratios. However, it has previously been shown that time of BCG vaccination does not have an 
effect on atopy (11), and therefore time of vaccine may not have impacted the association 
found in the current study. Finally, although a significant association was found between BCG 
and food sensitisation at a SPT  7mm when the odds ratio was adjusted, there may be 
residual confounding that was either not measured or not accounted for in the adjusted 
analyses. 
 
In conclusion, there was very little evidence of an association between BCG vaccination in 
children and food allergic sensitisation or food allergy. However, in a small subgroup, there 
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+ HepB at Birth) 
Age of 
child 
Option 3 in Private 
(2-4-6 months) 
At birth OPV(0) OPV(0) OPV (0) At birth OPV(0) 
BCG BCG BCG BCG 
  HBV1  
6 weeks OPV(1) OPV(1) OPV(1) 2 months OPV(1) 
RV (1) RV (1) RV (1) RV (1) 
PCV(1) PCV(1) PCV (1) PCV (1) 
DTaP-IPV/Hib (1)1 + 
HBV(1), or 
DTaP-IPV-Hib-HBV (1)1 
DTaP-IPV-Hib-HBV (1)2 DTaP-IPV-Hib-HBV (1)2 
or 
DTaP-IPV-HBV/Hib (1)2 
DTaP-IPV-Hib-HBV (1) or 
DTaP-IPV-HBV/Hib (1) 
10 weeks  RV3 (2) RV3 (2) 3 or 4 
months 
RV3(2) 
 PCV (2) PCV (2) PCV (2) 
DTaP-IPV/Hib (2) + 
HBV(2) or 
DTaP-IPV-Hib-HBV (2) 
DTaP-IPV/Hib (2) + 







14 weeks RV (2) RV3  (2 or 3) RV3  (2 or 3) 4 or 6 
months 
RV3  (2 or 3) 
PCV(2) PCV (3) PCV (3) PCV (3) 
DTaP-IPV/Hib (3) + 
HBV(3) or 
DTaP-IPV-Hib-HBV (3) 
DTaP-IPV/Hib (3) + 







9 months Measles (1) Measles (1) Measles (1) 9 months Measles (1) 
PCV(3) MCV (1 MCV (1) MCV (1) 
12-15 
Months 
 PCV (4)4 PCV (4)4 12-15 
months 
PCV (4)4 
 MMR (1) MMR (1) MMR (1) 
 Varicella5 (1) Varicella5 (1) Varicella5 (1) 
 Hepatitis A (repeat 6 
months later) 
Hepatitis A (repeat 6 
months later) 
Hepatitis A (repeat 6 months 
later) 
 MCV (2) MCV (2) MCV (2) 
18 
Months 
DTaP-IPV/Hib (4) or 
DTaP-IPV-Hib-HBV (4) 








18 months DTaP-IPV/Hib or 
DTaP-IPV-Hib-HBV (3) or 
DTaP-IPV-HBV/Hib (3) 
Measles (2)    




5-6 years DTaP or 
Tdap-IPV 
MMR (2) MMR (2) MMR (2) 
Varicella (2) Varicella (2) Varicella (2) 
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9 years HPV6 HPV7  (from 9 years) HPV78  (from 9 years) 9 years HPV7( from 9 years) 
12 years Td vaccine Tdap-IPV 8 Tdap-IPV 8 12 years Tdap-IPV 8 
 
Abbreviations: 
o OPV: Oral polio vaccine, 
o BCG: Bacille Calmette Guerin vaccine, 
o HBV: Hepatitis B vaccine, 
o RV: Rotavirus vaccine 
o Td vaccine: Tetanus & reduced amount of diphtheria vaccine 
o Tdap-IPV: (Quadrivalent): Tetanus & reduced amounts of diphtheria and acellular pertussis with inactivated polio vaccine 
o DTaP: Diphtheria, tetanus and acellular pertussis vaccine 
o DTaP-IPV/Hib: (Pentavalent): Diphtheria, tetanus, acellular pertussis / inactivated polio & haemophilus influenzae type b 
vaccine 
o DTaP-IPV-Hib-HBV: (Hexavalent): Diphtheria, tetanus, acellular pertussis / inactivated polio / haemophilus 
influenzae type b and hepatitis B vaccine, fully liquid. 
o DTaP-IPV-HBV/Hib: (Hexavalent): Diphtheria, tetanus, acellular pertussis / inactivated polio / haemophilus 
influenzae type b and hepatitis B vaccine, requiring constitution 
o HPV: Human papillomavirus vaccine 
o MCV: Meningococcal (Groups A, C, W and Y) polysaccharide diphtheria toxoid conjugate vaccine 
o MMR: Measles, mumps and rubella vaccine o PCV: Pneumococcal conjugated vaccine 
 
www.amayeza-info.co.za/   
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Appendix 2:  Vaccine Trade Names 
ANTIGEN TRADE NAME AGE GROUP 
BCG BCG® Usually at birth only but in certain cases up to 1 year 
CHICKENPOX VARILRIX® 9 months and older 





Children 8 weeks to 2 years 
6 weeks to 5 years 
DTaP-IPV/Hib PENTAXIM® Children 6 weeks to 2 years. This product will be phased out in 
2015 
HEPATITIS A AVAXIM 80® or HAVRIX JUNIOR® 1 – 15 years 
HEPATITIS B (HBV) HEBERBIOVAC®, EUVAX® or ENGERIX-B® 0-adulthood (dose according to age) 
HPV GARDASIL® (quadrivalent) or 
 
CERVARIX® (bivalent) 
Gardasil ages 9-45 years (girls and women) 
Gardasil ages 9-26 years (boys and men) 
Cervarix 9 years and older 
MCV (A,C,W,Y) MENACTRA® 9 months – 23 months; 2 doses 3 months apart. 
≥ 2years – 55 years – a single dose 
MEASLES ROUVAX® 9 months and older 
MEASLES, MUMPS, RUBELLA 
(MMR) 
TRIMOVAX® or PRIORIX® 1 year - adulthood 
OPV OPV-MERIEUX® or POLIORAL® 0-Adulthood (not generally recommended in adulthood due to 
VAPP – vaccine associated paralytic polio) 
PNEUMOCOCCAL (PCV) PREVENAR-13® 
SYNFLORIX® 
Children 6 weeks to 5 years 
Children 6 weeks to 5 years 
ROTAVIRUS (RV) ROTARIX® 
 
ROTATEQ® 
First dose from 6 weeks, second before 24 weeks 
First dose from 6 weeks of age and by 12 weeks, last dose before 
32 weeks 
Td DIFTAVAX® 6 years and older 
Tdap-IPV ADACEL QUADRA® 
BOOSTRIX TETRA® 
from 3 Years of age 
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Appendix 3:  Letter of Approval from HREC 
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Appendix 5:  Instructions from the Annals of Allergy, Asthma & Immunology for 
manuscript 
_________________________________________________________________________ 
General Information  
The Annals of Allergy, Asthma & Immunology is the official journal of the American College of Allergy, 
Asthma and Immunology. The Annals acceptance rate is approximately 32%. Median turnaround time 
from submission to first decision is 22 days, from submission to acceptance is 78 days, and acceptance 
to publication is 86 days.  
 
Authors are responsible for all statements, opinions, conclusions, and methods of presenting their 
data in articles submitted to the Annals of Allergy, Asthma & Immunology for possible publication. The 
views of authors as presented in their articles do not necessarily represent the opinions of the Annals 
of Allergy, Asthma & Immunology editorial staff or the American College of Allergy, Asthma and 
Immunology.  
The purpose of these instructions is to provide authors with clear and concise guidelines for preparing 
a manuscript in acceptable Annals style. In general, exceptions to the published guidelines are not 
made. Authors who believe they have compelling reasons to alter and/or exceed the published 
guidelines may appeal to the editorial office for a variance PRIOR TO submission. Appeals may be sent 
to annallergy@umc.edu. Otherwise, manuscripts that do not meet these guidelines will be returned 
to the corresponding author for revision prior to any further consideration for peer review.  
Editorial Policies for Authors  
Authorship  
It is assumed that a submitted manuscript is the work of the listed authors and represents the effort 
to generate the manuscript. While outside editorial assistance may be utilized, "ghost written" articles 
are not accepted for review by the Annals. By submitting a manuscript the authors certify that they 
have (collectively) personally written at least 90 percent of the manuscript.  
Authorship Requirements  
In order to be included in the list of authors, an individual must meet all the following requirements 
approved by the International Committee of Medical Journal Editors (ICMJE): (1) made substantial 
contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) 
drafted the article or reviewed it critically for important intellectual content; (3) given final approval 
of the version to be published; and (4) agrees to be accountable for all aspects of the work related to 
its accuracy or integrity. 
Manuscript Preparation  
NOTE: Manuscripts that do not adhere to the following requirements will be returned to the 
corresponding author before peer review is initiated.  
 
Basic Formatting (Page Setup/Fonts)  
Each manuscript submission item, as described later in this document, should be formatted as follows 
(unless otherwise specified in the Article Type/Organization section of this document):  
1. Be in a standard font such as Times New Roman, Arial, or Courier, size 12,  
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2. Be attached as a separate submission item,  
3. Be double-spaced and have a one inch margin on all side, and  
4. Display page numbers in the upper right corner of each page and continuous Line numbers 
(i.e., 1, 2, 3 etc.) in the left-hand margin of the Manuscript and Reference Submission items. Do NOT 
restart numbering from each page. Line numbering can be added from the File/Page Setup menu of 
word processing programs and should be continuous throughout the manuscript text file, and  
5. File names should NOT contain brackets [ ].  
Abstracts  
Original research, systematic reviews, and meta-analyses require structured abstracts. Structured 
abstract should not exceed 255 words. Abstracts should NOT be included on the title page, but 
recorded during the online submission process. Please refer to the Article Type/Organization section 
of this document for the structured abstract formats.  
Manuscript Text File  
All submissions require a manuscript text file, unless otherwise specified in the Article 
Type/Organization section of this document.  
The text file should display page numbers in the upper right corner of each page and continuous line 
numbers (i.e., 1, 2, 3 etc.) in the left-hand margin of the submission item. Do NOT restart numbering 
from each page. Line numbering can be added from the File/Page Setup menu of word processing.  
In order to ensure a double-blind review, it is imperative that author identifying information not be 
included in the manuscript text. Abstracts, acknowledgments, E-supplement material, figures, tables 
and references should NOT be included in the manuscript text file.  
Text should be divided into the following section headings in this order, unless otherwise specified in 
the Article Type/Organization section of this document.  
Introduction: Provide an overview of the scope and relevance of the study. The introduction should 
be brief and state the problem being investigated, its contextual background, and the reasons for 
conducting the research.  
Methods: Describe the design (randomized, double-blind, placebo control), subjects, setting (general 
community, private practice, and hospital), interventions, and main outcome measures. For all 
research studies involving animal or human subjects or research material derived from humans, 
appropriate institutional review board (IRB) review and approval is required and the manner in which 
informed consent was obtained from the study participants (i.e., oral or written) should be stated in 
the Methods section of the manuscript. Studies exempted from IRB approval by their respective 
boards should be stated in the Methods section. If no formal ethics committee is available, authors 
should indicate in the Methods section that procedures followed were in accordance with the Helsinki 
Declaration as revised in 2013 (  http://www.wma.net/en/30publications/10policies/b3/). When 
reporting experiments on animals, authors should indicate whether the institutional and national 
guide for the care and use of laboratory animals was followed. Such review and approval or waiver 
should also be stated in the Methods sections of the manuscript.  
Results: Describe the experimental data and results as well as the particular statistical significance of 
the data.  
Discussion: Provide and quantify the main outcomes of the study. Identify limitations of the presented 
data including plausible explanations for discrepancies between the data and the literature, any 
differences not expected from the initial hypothesis presented in the introduction and a measured 
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description of the conclusions of the study with implications for future research, biological 
understanding and/or clinical applications.  
For guidance regarding grammar, punctuation, and scientific writing see the AMA Manual of Style, 
10th ed. New York: Oxford Press; 2007.  
Acknowledgements  
All persons who have made substantial contributions to the work reported in the manuscript (e.g., 
data collection, analysis, or writing or editing assistance) but who do not fulfill the authorship criteria 
should be named with their specific contributions in the Acknowledgments section.  
References  
All submissions require a Reference file, unless otherwise specified in the Article Type/Organization 
section of this document. Authors are responsible for the accuracy and completeness of their 
references and format. NOTE: Refer to the Article Types/Organization section of this document as 
there are a maximum number of references for each category.  
1. Be numbered consecutively in the order in which they are first cited in the text.  
2. Be identified with superscript Arabic numerals in text, tables and legends.  
3. Be recorded during the electronic submission process.  
4. Reflect the current state of knowledge being cited. As a rule, the Annals expects citations to 
be within the last 5 years unless the reference a) represents a seminal article that most would agree 
has persistent value; b) there is no more recent article that adequately represents the cited statement 
and/or c) the article represents the initial description of the finding/event being cited. In all instances, 
the reference list will be subject to review and editing as determined by the peer review process.  
5. Journal names should be abbreviated according to Index Medicus.  
6. All authors up to 6 should be listed; if there are more than 6 authors, list the first 3 followed 
by "et al."  
 
Tables  
Tables should be prepared using Microsoft Word. Each table accompanying a submission should be 
uploaded as a separate submission item. Tables should:  
1. Be numbered in the order in which they are first cited in the text.  
2. Be recorded on the title page and during the electronic submission process.  
3. Have a concise heading (no more than 30 words).  
4. Be comprehensible without reference to the text of the article. Use horizontal lines only at 
the top and bottom of the table and between column headings and the body of the table. Use no 
vertical lines.  
5. To easily identify files, please ensure numbering, type and format is reflected in the file name. 
For example, Table 1.xls equals Table 1 in Microsoft Excel format. 
6. Abbreviations should be defined in alphabetical order at the bottom of the table, e.g., 
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Figures  
For best print quality, the Annals and Elsevier recommend figures be submitted in TIFF or EPS format. 
Elsevier, however, will accept electronic artwork in JPEG, PDF and Microsoft Office (Word, Excel, and 
PowerPoint) formats. For more information on submitting graphics, please visit  
http://www.elsevier.com/artwork. Each figure accompanying a submission should be uploaded as a 
separate submission item.  
Figures (graphs, charts, photographs, and illustrations) should:  
1. Be numbered in the order in which they are first cited in the text.  
2. Be recorded on the title page and during the electronic submission process.  
3. To easily identify files, please ensure numbering, type and format is reflected in the file name. 
For example, FIG1.TIF equals Figure 1 in TIFF format, FIG2.EPS equals Figure 2 in EPS format.  
4. Figure legends/captions should NOT be included in the figure file, but uploaded as a separate 
submission item. 
Figure Legend  
Figure legends/captions should be prepared using Microsoft Word. A single figure legend for all figures 
should be uploaded as a separate submission item. Figure Legends should:  
1. Have a concise legend/caption (no more than 30 words). 
2. Be uploaded as a single document.  
Article Types/Organization  
The Annals publishes original articles, reviews, editorials, letters, correspondence and many other 
categories of articles. Topics of interest include all subjects that relate to the practice of allergy-
immunology. The most frequent published types are described herein.  
Original Articles  
Original articles should have a structured abstract of 255 words or less with the following headings: 
Background, Objective, Methods, Results, and Conclusion. A maximum of 12 keywords, 60 references, 
and a combined total of 8 tables and/or figures are allowed. Text should not exceed 4,000 words and 
should be organized into the following headings: Introduction, Methods, Results, and Discussion. Each 
submission must be comprised of the following submission items:  
1. Cover letter 
2. Title page 
3. Manuscript 
4. Acknowledgments, if applicable 
5. References 
6. Figures, if applicable 
7. Figure legend, if applicable 
8. Tables, if applicable 
9. eSupplements, if applicable 
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Appendix 6: Table: Associations between immunisation status and SPT 1mm,  
3mm and  7mm in urban participants 
Outcome Vaccine OR 95% CI *adjusted 
OR 
95%CI 
SPT  1 BCG 0.3 0.03  -  3.4 0.2 0.02 -  2.7 
 OPV(0) 0.3 0.06   - 1.7 0.3 0.1  -   1.5 
 OPV(1) 1    
 RV (1) 1    
 DTaP-IPV/Hib (1) 1    
 HBV(1) 1    
 PCV(1) 1    
 DTaP-IPV/Hib (2)  1    
 HBV(2) 1    
 RV (2) 1    
 DTaP-IPV/Hib (3)  1    
 HBV(3) 1    
 PCV(2) 1    
 MV(1) 1.6 0.2 -  12.3 1.8 0.2 -   14.9 
 PCV(3) 1.01 0.2 –  4.5 1.1 0.2 -    5.0 
 DTaP-IPV/Hib (4)  1 0.4  -  2.5 0.9 0.4   - 2.4 
 MV2 1 0.4   - 2.5 0.9 0.4   - 2.4 
SPT  3 BCG 0.2 0.02 – 2.4 0.2 0.02 -  2.7 
 OPV(0) 0.2 0.04 – 1.2 0.3 0.1  -   1.5 
 OPV(1) 1    
 RV (1) 1    
 DTaP-IPV/Hib (1) 1    
 HBV(1) 1    
 PCV(1) 1    
 DTaP-IPV/Hib (2)  1    
 HBV(2) 1    
 RV (2) 1    
 DTaP-IPV/Hib (3)  1    
 HBV(3) 1    
 PCV(2) 1    
 MV(1) 1.1 0.1  -  8.6 1.8 0.2  -  14.9 
 PCV(3) 0.7 0.2  -  3.1 1.1 0.2 -   5.0 
 DTaP-IPV/Hib (4)  0.8 0.3 – 2.2 0.8 0.3   - 2.3 
 MV2 0.8 0.3 – 2.2 0.8 0.3   - 2.3 
SPT  7 BCG 0.09 0.08 - 0.97 0.05 0.004  -  0.6 
 OPV(0) 0.2 0.02 -  1.9 0.2 0.02 -  1.6 
 OPV(1) 1    
 RV (1) 1    
 DTaP-IPV/Hib (1) 1    
 HBV(1) 1    
 PCV(1) 1    
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 DTaP-IPV/Hib (2)  1    
 HBV(2) 1    
 RV (2) 1    
 DTaP-IPV/Hib (3)  1    
 HBV(3) 1    
 PCV(2) 1    
 MV(1) 0.4 0.1  -  3.5 0.5 0.1 - 4.6 
 PCV(3) 0.6 0.1  -  4.8 0.7 0.1 - 5.7 
 DTaP-IPV/Hib (4)  0.8 0.2 – 3.5 0.6 0.1   - 3.1 
 MV2 0.8 0.2 – 3.5 0.6 0.1   -  3.1 
*odds ratios adjusted for  age at enrolment, gender, breast fed, number of older children in the house and 
clinically diagnosed eczema 
 
 
Appendix 7: Table: Association between immunisation status and food allergy in 
the urban participants 
Outcome Vaccine OR 95% CI *adjusted 
OR 
95%CI 
Food allergy BCG 1    
 OPV(0) 0.2 0.02  -  1.8 0.1 0.02  -  1.3 
 OPV(1) 1    
 RV (1) 1    
 DTaP-IPV/Hib (1) 1    
 HBV(1) 1    
 PCV(1) 1    
 DTaP-IPV/Hib (2)  1    
 HBV(2) 1    
 RV (2) 1    
 DTaP-IPV/Hib (3)  1    
 HBV(3) 1    
 PCV(2) 1    
 MV(1) 1    
 PCV(3) 0.6 0.1 – 4.5 0.6 0.1 -   5.0 
 DTaP-IPV/Hib (4)  0.9 0.2 – 4.1 1.1 0.2   -  5.4 
 MV2 0.9 0.2 – 4.1 1.1 0.2   -  5.3 
      
*odds ratios adjusted for  age at enrolment, gender, breast fed, number of older children in the house and 







Part D Appendices 
 
Appendix 8: Table: Association between immunisation status and self-reported 
eczema, asthma and hay fever for urban participants 
Outcome Vaccine OR 95% CI *adjusted 
OR 
95%CI 
Self-reported  BCG 1    
asthma OPV(0) 0.6 0.1  -  5.5 0.5 0.1    -  4.6 
 OPV(1) 0.4 0.04  -  3.7 0.3 0.03  -  3.1 
 RV (1) 1    
 DTaP-IPV/Hib (1) 1    
 HBV(1) 1    
 PCV(1) 1    
 DTaP-IPV/Hib (2)  1    
 HBV(2) 1    
 RV (2) 1    
 DTaP-IPV/Hib (3)  0.4 0.04 - 3.7 0.3 0.03  -   2.5 
 HBV(3) 1    
 PCV(2) 1    
 MV(1) 1    
 PCV(3) 1    
 DTaP-IPV/Hib (4)  0.8 0.4 – 1.9 0.7 0.3   -  1.7 
 MV2 0.7 0.3 – 1.5 0.6 0.2   -  1.4 
Self-reported  BCG 1    
Hay fever OPV(0) 0.7 0.1 - 4 0.7 0.1  - 3.7 
 OPV(1) 0.4 0.1 – 2.6 0.3 0.1  - 2.4 
 RV (1) 1    
 DTaP-IPV/Hib (1) 1    
 HBV(1) 1    
 PCV(1) 1    
 DTaP-IPV/Hib (2)  1    
 HBV(2) 1    
 RV (2) 1    
 DTaP-IPV/Hib (3)  1.09 0.1 - 10.5 0.9 0.1 – 8.8 
 HBV(3) 1    
 PCV(2) 1    
 MV(1) 0.96 0.3 - 3.7 1.0 0.3 – 4.0 
 PCV(3) 0.99 0.3  - 3.2 1.0 0.3 -   3.3 
 DTaP-IPV/Hib (4)  0.6 0.3 – 1.1 0.6 0.3    - 1.1 
 MV2 0.7 0.4 – 1.3 0.7 0.4    -  1.3 
Self-reported  BCG 1    
eczema OPV(0) 0.7 0.1 -  3.6 0.6 0.1  - 3.4 
 OPV(1) 0.97 0.1 – 9.4 1.0 0.1  - 10 
 RV (1) 1    
 DTaP-IPV/Hib (1) 1    
 HBV(1) 1    
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 PCV(1) 1    
 DTaP-IPV/Hib (2)  1    
 HBV(2) 1    
 RV (2) 1.3 0.1 – 11.7 1.4 0.2  - 13 
 DTaP-IPV/Hib (3)  0.97 0.1  - 9.4 1.0 0.1  - 10 
 HBV(3) 0.7 0.06 -  7.2 0.7 0.1  -  7.7 
 PCV(2) 1    
 MV(1) 0.9 0.2 -  3.3 0.8 0.2   -   3.1 
 PCV(3) 0.9 0.3  -  2.8 0.9 0.3   -   2.8 
 DTaP-IPV/Hib (4)  1.4 0.7 – 2.9 1.2 0.6    -  2.6 
 MV2 1.6 0.8 – 3.5 1.4 0.7    -  3.1 
      
*odds ratios adjusted for  age at enrolment, gender, breast fed, number of older children in the house and 
clinically diagnosed eczema. Self-reported eczema odds ratio adjusted for age at enrolment, gender, breast fed 
and number of older children in the house. 
 
 
Appendix 9: Table: Associations between immunisation status and SPT 1mm,  
3mm and  7mm in rural participants 
Outcome Vaccine OR 95% CI *adjusted 
OR 
95%CI 
SPT  1 OPV(1) 1    
 PCV(2) 1    
 MV(1) 1    
 PCV(3) 0.7 0.1 - 5.8 0.6 0.1   -  5.4 
 DTaP-IPV/Hib (4)  1.4 0.2 - 11.1 1.4 0.2   - 12.0 
 MV2 1.4 0.2 - 11.1 1.4 0.2   - 11.7 
SPT  3 OPV(1) 1    
 PCV(2) 1    
 MV(1) 1    
 PCV(3) 1    
 DTaP-IPV/Hib (4)  1    
 MV2 1    
SPT  7 OPV(1) 1    
 PCV(2) 1    
 MV(1) 1    
 PCV(3) 1    
 DTaP-IPV/Hib (4)  1    
 MV2 1    
      
*odds ratios adjusted for  age at enrolment, gender, breast fed, number of older children in the house and 
clinically diagnosed eczema 
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Appendix 10: Table: Association between immunisation status and self-reported 
eczema, asthma and hay fever for rural participants 
Outcome Vaccine OR 95% CI *adjusted 
OR 
95%CI 
Self-reported  OPV(1) 1    
asthma PCV(2) 1    
 MV(1) 1    
 PCV(3) 1    
 DTaP-IPV/Hib (4)  1    
 MV2 1    
Self-reported  OPV(1) 1    
Hay fever PCV(2) 1    
 MV(1) 0.3 0.04 - 2.7 0.4 0.1   -  3.5 
 PCV(3) 0.5 0.1  - 3.7 0.5 0.1   -  4.0 
 DTaP-IPV/Hib (4)  0.9 0.1 - 7.3 0.9 0.1  -  8.1 
 MV2 0.9 0.1  - 7.3 0.8 0.1   - 7.7 
Self-reported  OPV(1) 1    
eczema PCV(2) 1    
 MV(1) 0.2 0.02  -  1.6 0.2 0.03  -   2.4 
 PCV(3) 0.3 0.03  - 2.3 0.3 0.03 -   2.9 
 DTaP-IPV/Hib (4)  0.4 0.04  -  3.6 0.2 0.02  -  2.4 
 MV2 0.4 0.04 -  3.6 0.3 0.02   -  2.8 
*odds ratios adjusted for  age at enrolment, gender, breast fed, number of older children in the house and 
clinically diagnosed eczema. Self-reported eczema odds ratio adjusted for age at enrolment, gender, breast fed 
and number of older children in the house. 
 
